

0001683168-24-00571110-Q CNS Pharmaceuticals, Inc. 20240814202408141722517225172252 0 0001683168-24-005711 10-Q 44 20240630 20240814 20240814 CNS Pharmaceuticals, Inc. 0001729427 2834 822318545 Nv 1231 10-Q 301-39126 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 10-Q cns lq-063024.htm FORM 10-Q FOR JUNE 2024 CNS Pharmaceuticals, Inc. 10-Q false -12-31 2024 Q2 0001729427 0001729427 2024-01-01 2024-06-30

0001729427 2024-08-14 0001729427 2024-06-30 0001729427 2023-12-31 0001729427 2024-04-01 2024-06-30 0001729427 2023-04-01 2023-06-30 0001729427 2023-01-01 2023-06-30 0001729427 us-gaap:CommonStockMember 2023-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001729427 us-gaap:RetainedEarningsMember 2023-12-31 0001729427 us-gaap:CommonStockMember 2024-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001729427 us-gaap:RetainedEarningsMember 2024-03-31 0001729427 us-gaap:CommonStockMember 2022-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001729427 us-gaap:RetainedEarningsMember 2022-12-31 0001729427 us-gaap:CommonStockMember 2023-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001729427 us-gaap:RetainedEarningsMember 2023-03-31 0001729427 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001729427 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001729427 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001729427 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001729427 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001729427 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001729427 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001729427 us-gaap:CommonStockMember 2024-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001729427 us-gaap:RetainedEarningsMember 2024-06-30 0001729427 us-gaap:CommonStockMember 2023-06-30 0001729427 us-gaap:RetainedEarningsMember 2023-06-30 0001729427 us-gaap:CommonStockMember 2022-11-27 2022-11-28 0001729427 2024-06-03 2024-06-04 0001729427 CNSP:WarrantsMember 2024-01-01 2024-06-30 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001729427 CNSP:UnvestedPerformanceUnitsMember 2024-01-01 2024-06-30 0001729427 CNSP:OptionsMember 2024-01-01 2024-06-30 0001729427 CNSP:WarrantsMember 2023-01-01 2023-06-30 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2023-01-01 2023-06-30 0001729427 CNSP:UnvestedPerformanceUnitsMember 2023-01-01 2023-06-30 0001729427 CNSP:OptionsMember 2023-01-01 2023-06-30 0001729427 CNSP:November2023NoteMember 2023-11-28 0001729427 CNSP:November2023NoteMember 2023-11-27 2023-11-28 0001729427 CNSP:November2023NoteMember 2024-06-30 0001729427 us-gaap:CommonStockMember 2024-05-01 0001729427 us-gaap:CommonStockMember 2024-06-30 0001729427 2024-05-01 0001729427 CNSP:EquityPlan2020Member 2024-04-30 0001729427 CNSP:EquityPlan2020Member 2024-04-29 2024-04-30 0001729427 2024-01-29 0001729427 CNSP:SeriesAWarrantsMember 2024-01-29 0001729427 CNSP:SeriesBWarrantsMember 2024-01-29 0001729427 CNSP:PreFundedWarrantsMember 2024-01-29 0001729427 CNSP:CommonWarrantsMember 2024-01-29 0001729427 2024-04-02 0001729427 2024-01-31 2024-02-01 0001729427 CNSP:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember CNSP:InstitutionalInvestorMember 2024-06-13 2024-06-14 0001729427 CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember CNSP:InstitutionalInvestorMember 2024-06-14 0001729427 CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember CNSP:InstitutionalInvestorMember 2024-06-13 2024-06-14 0001729427 CNSP:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember CNSP:InstitutionalInvestorMember 2024-06-25 2024-06-26 0001729427 CNSP:SecuritiesPurchaseAgreementsMember CNSP:CommonStockWarrantsMember CNSP:InstitutionalInvestorMember 2024-06-26 0001729427 CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember CNSP:InstitutionalInvestorMember 2024-06-26 0001729427 CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember CNSP:InstitutionalInvestorMember 2024-06-25 2024-06-26 0001729427 CNSP:Plan2017Member 2024-06-30 0001729427 CNSP:Plan2020Member 2024-06-30 0001729427 CNSP:Plan2020Member 2023-08-08 2024-08-09 0001729427 CNSP:MachineryMember 2024-01-17 2024-01-19 0001729427 CNSP:BoardOfDirectorsMember 2024-01-17 2024-01-19 0001729427 CNSP:BoardOfDirectorsMember 2024-01-19 0001729427 CNSP:ShareholderMember 2024-04-06 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember 2024-04-06 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember CNSP:ShareholderMember 2024-04-06 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember 2024-04-06 2024-04-07 0001729427 us-gaap:StockOptionMember 2024-01-01 2024-06-30 0001729427 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001729427 us-gaap:StockOptionMember 2024-06-30 0001729427 2024-01-28 2024-01-29 0001729427 CNSP:WarrantExercisePriceMember 2024-01-01 2024-06-30 0001729427 CNSP:WarrantsMember 2024-01-01 2024-06-30 0001729427 CNSP:OfficersMember 2022-04-27 2022-04-28 0001729427 CNSP:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2024-04-06 2024-04-07 0001729427 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-06 2024-04-07 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001729427 CNSP:PerformanceUnitsMember 2022-04-27 2022-04-28 0001729427 CNSP:PerformanceUnitsMember 2024-01-01 2024-06-30 0001729427 CNSP:PerformanceUnitsMember 2024-06-30 0001729427 CNSP:StockOptionsMember 2023-12-31 0001729427 CNSP:StockOptionsMember 2024-01-01 2024-06-30 0001729427 srt:MinimumMember 2024-01-01 2024-06-30 0001729427 srt:MaximumMember 2024-01-01 2024-06-30 0001729427 CNSP:WarrantsMember 2023-12-31 0001729427 CNSP:WarrantsMember 2024-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001729427 CNSP:PerformanceUnitsMember 2023-12-31 0001729427 CNSP:MrClimacoMember 2021-02-05 2021-02-06 0001729427 CNSP:OfficersMember 2024-03-31 000172

Cash and cash equivalents, at beginning of period: \$ 548,721.00 \$ 10,055,407.00 \$ 10,055,407.00 Cash and cash equivalents, at end of period: \$ 1,491,559.00 \$ 4,279,251.00

Supplemental disclosures of cash flow information: Cash paid for interest: \$ 11,088.64 \$ 9,086.64 Cash paid for income taxes: \$ 0.00 \$ 0.00

Supplemental disclosure of non-cash investing and financing activities: Reclassification of deferred offering costs to equity: \$ 202,859.00 \$ 0.00

See accompanying notes to the unaudited financial statements.

The Company is a Clinical Pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates. On August 25, 2022, the stockholders of the Company approved an amendment to the Company's amended and restated articles of incorporation to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30. The reverse stock split became effective on November 28, 2022 on a 1-for-30 basis without any change in the par value per share, which remained at \$0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes. On April 30, 2024, the stockholders of the Company approved an amendment to the Company's amended and restated articles of incorporation to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50. The reverse stock split became effective on June 4, 2024 on a 1-for-50 basis without any change in the par value per share, which remained at \$0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.

Summary of Significant Accounting Policies Basis of Presentation - The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2024. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2023 included in our Form 10-K filed with the SEC on April 1, 2024 (Form 10-K). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. A Liquidity and Going Concern - These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.

Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of \$250,000. The amount in excess of the FDIC insurance as of June 30, 2024 was \$1,241,559. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units. Restricted Stock Units (RSUs) - Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. Performance Units (PUs) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board. Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of June 30, 2024, the Company's potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 1,551,422 common shares, unvested restricted stock units of 5,475 common shares, unvested performance units of 577 and options for 12,177 common shares, respectively. As of June 30, 2023, the Company's potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 45,399 common shares, unvested restricted stock units of 193 common shares, unvested performance units of 577 and options for 2,591 common shares, respectively.

Note Payable - On November 28, 2023, the Company entered into a short-term note payable for an aggregate of \$329,571, bearing interest at 9.74% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on October 8, 2024. As of June 30, 2024 the Company's note payable balance was \$123,248.

Equity - The Company has authorized 75,000,000 shares of common stock having a par value of \$0.001 per share. In addition, the Company authorized 5,000,000 shares of preferred stock to be issued having a par value of \$0.001. The specific rights of the preferred stock shall be determined by the board of directors. On May 2, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of the Company's authorized shares of common stock from 75,000,000 shares to 300,000,000 shares.

On August 25, 2022, the stockholders of the Company approved an amendment to the Company's amended and restated articles of incorporation to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30, with such ratio to be determined in the discretion of the Company's board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company's board of directors in its sole discretion prior to the one-year anniversary of the annual meeting. Pursuant to such authority granted by the Company's stockholders, the Company's board of directors approved a one-for-thirty (1:30) reverse stock split of the Company's common stock and the filing of the Amendment to effectuate the reverse split. The reverse stock split became effective on November 28, 2022 on a 1-for-30 basis without any change in the par value per share, which remained at \$0.001.

On April 30, 2024, the stockholders of the Company approved an amendment to the Company's amended and restated articles of incorporation to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined in the discretion of the Company's board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company's board of directors in its sole discretion prior to the one-year anniversary of the annual meeting. Pursuant to such authority granted by the Company's stockholders, the Company's board of directors approved a one-for-fifty (1:50) reverse stock split of the Company's common stock and the filing of the Amendment to effectuate the reverse split. The reverse stock split became effective on June 4, 2024 on a 1-for-50 basis without any change in the par value per share, which remained at \$0.001.

On April 30, 2024, the Company held its scheduled 2024 Annual Meeting of Stockholders at which the Company's stockholders approved amendments to the Company's 2020 Equity Plan (the 2020 Plan), including an increase in the number of shares of common stock, par value \$0.001 per share, authorized for issuance under the 2020 Plan by 70,000 shares. As amended, the number of shares of the common stock that may be issued under the 2020 Plan is 86,916 shares (this includes the 70,000 share increase).

Common Stock - On January 29, 2024, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (AGP) and Maxim Group LLC (Maxim) and collectively with AGP, the Placement Agents (the Placement Agreement) for the public offering by the Company of (i) 44,314 shares (the Pre-Funded Warrants); (ii) Series A Warrants to purchase up to an aggregate of 266,667 shares of Common Stock (the Series A Warrants); and (iv) Series B Warrants to purchase up to an aggregate of 266,667 shares of Common Stock (the Series B Warrants), and together with the Series A Warrants, the Common Warrants (the Common Warrants). The Common Warrants and Pre-Funded Warrants are collectively referred to herein as the Warrants. The combined purchase price of one share of Common Stock and accompanying Common Warrants was \$15.00 and the combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was \$14.95. In connection with the offering, the Company entered into a Securities Purchase Agreement (the Purchase Agreement) with certain institutional investors that participated in the offering. As of April 1, 2024, 44,094 of the Pre-Funded Warrants have been exercised. The closing of the sales of these securities occurred on February 1, 2024. The net proceeds to the Company from the offering were \$3,331,000, after deducting the placement agents' fees and other offering expenses.

On June 14, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 336,000 shares of the Company's common stock and pre-funded warrants to purchase 30,000 shares of common stock in lieu thereof (the June 14 Pre-Funded Warrants) in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 366,000 shares of common stock (the June 14 Common Warrants). The combined purchase price of one share of common stock (or pre-funded warrant in lieu thereof) and accompanying June 14 Common Warrant was \$3.75. The closing of this offering and private placement occurred on June 17, 2024. Subject to certain ownership limitations, each of the June 14 Common Warrants is immediately exercisable, has an exercise price of \$3.62 per share, and expire five years from the date of issuance. Subject to certain ownership limitations, each June 14 Pre-Funded Warrant is exercisable into one share of common stock at a price per share of \$0.001 (as adjusted from time to time in accordance with the terms thereof). The gross proceeds to the Company from the offering was approximately \$1.37 million, resulting in net proceeds, after payment of commissions and expenses, received by the Company of \$1,203,259.

On June 26, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 568,000 shares of the Company's common stock in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 568,000 shares of common stock (the June 26 Common Warrants). The combined purchase price of one share of common stock and accompanying June 26 Common Warrant was \$2.45. The closing of the offering and private placement occurred on June 27, 2024 (the Closing Date). Subject to certain ownership limitations, each of the June 26 Common Warrants is immediately exercisable, has an exercise price of \$2.32 per share, and expire five years from the date of issuance. The June 26 Common Warrants may only be exercised on a cashless basis if there is no registration statement registering, or a prospectus contained therein is not available for, the resale of the shares of common stock underlying the June 26 Common Warrants. The gross proceeds to the Company from the offering were approximately \$1.39 million resulting in net proceeds, after payment of commissions and expenses, received by the Company of \$1,221,154.

Stock Options - In 2017, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2017 Stock Plan (the 2017 Plan). The 2017 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 1,334 shares of common stock. In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the 2020 Plan). The 2020 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 2,000 shares of common stock. The 2020 Plan was amended effective as of August 9, 2023, which was approved by the Company's stockholders at the Company's annual meeting on September 14, 2023. The amendment increased the 2020 Plan by 14,916 shares of common stock.

On January 19, 2024, the Board of Directors of the Company approved the issuance of 249 options to Ms. Mahery as compensation for her appointment to our Board of Directors. The options have a ten-year term at an exercise price of \$12.65 and vest in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was \$2,728. On April 7, 2024, the Board of Directors approved grants of 5,330 options to officers, employees, and board of directors. The options have a ten-year term at an exercise price of \$12.93. Of the 5,330 options issued, 1,750 options vest on the first anniversary or at the time of the 2025 shareholder meeting, whichever occurs first and 3,580 options vest in 36 equal monthly installments over 3 years. The total fair value of these option grants at issuance was \$58,335.

During the six months ended June 30, 2024 and 2023, the Company recognized \$412,749 and \$544,248 of stock-based compensation, respectively, related to outstanding stock options. At June 30, 2024, the Company had \$366,400 of unrecognized expenses related to outstanding options.

The following table summarizes the stock option activity for the six months ended June 30, 2024:

Schedule of stock option activity
OptionsA Weighted-Average Exercise Price Per Share Outstanding, December 31, 2023A \$ 6.598A \$ 1,020.47A GrantedA 5,579A A 12.92A ExercisedA 0A A 0A ForfeitedA 0A A 0A ExpiredA 0A A 0A Outstanding, June 30, 2024A 12,177A

[illegible]

achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under Item 1A. **Risk Factors** of our Form 10-K for the year ended December 31, 2023 and in other filings made by us from time to time with the SEC. **A** While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10-Q may describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. **A** Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, and we do not intend to do so. **A** Forward-looking statements include, but are not limited to, statements about: **A** **A** **A** **A** our ability to maintain our listing on the Nasdaq Capital Market; **A** **A** **A** **A** **A** our ability to obtain additional funding to develop our product candidates; **A** **A** **A** **A** the need to obtain regulatory approval of our product candidates; **A** **A** **A** **A** the success of our clinical trials through all phases of clinical development; **A** **A** **A** **A** **A** **A** **A** **A** compliance with obligations under intellectual property licenses with third parties; **A** **A** **A** **A** **A** any delays in regulatory review and approval of product candidates in clinical development; **A** **A** **A** **A** **A** our ability to commercialize our product candidates; **A** **A** **A** **A** **A** market acceptance of our product candidates; **A** **A** **A** **A** **A** competition from existing products or new products that may emerge; **A** **A** **A** **A** **A** potential product liability claims; **A** **A** **A** **A** **A** our dependency on third-party manufacturers to supply or manufacture our products; **A** **A** **A** **A** **A** our ability to establish or maintain collaborations, licensing or other arrangements; **A** **A** **A** **A** **A** our ability and third parties' abilities to protect intellectual property rights; **A** **A** **A** **A** **A** our ability to adequately support future growth; and **A** **A** **A** **A** **A** our ability to attract and retain key personnel to manage our business effectively. **A** We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-Q in the case of forward-looking statements contained in this Form 10-Q. **A** You should not rely upon forward-looking statements as predictions of future events. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not rely on any of the forward-looking statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. **A** Overview **A** We are a clinical pharmaceutical company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors, based on intellectual property that we license under license agreements with Houston Pharmaceuticals, Inc. (aHPI) and The University of Texas M.D. Anderson Cancer Center (aUTMDACC) and own pursuant to a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. (aReata). **A** **A** **A** **A** **A** **A** **A** **A** **A** We believe our lead drug candidate, Berubicin, may be a significant development in the treatment of Glioblastoma and other CNS malignancies, and if approved by the U.S. Food and Drug Administration (aFDA), could give Glioblastoma patients an important new therapeutic alternative to the current standard of care. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly, and they are supported by a large network of blood vessels. Berubicin is an anthracycline, which is a class of drugs that are among the most powerful and extensively used chemotherapy drugs known. Based on limited clinical data, we believe Berubicin is the first anthracycline that appears to cross the blood brain barrier (aBBB) in significant concentrations targeting brain cancer cells. While our focus is currently on the development of Berubicin, we are also in the process of attempting to secure intellectual property rights to additional compounds that we plan to develop into drugs to treat CNS and other cancers. **A** Berubicin was discovered at UTMDACC by Dr. Waldemar Priebe, the founder of the Company. Through a series of transactions, Berubicin was initially licensed to Reata. Reata initiated several Phase I clinical trials with Berubicin for CNS malignancies, one of which was for malignant gliomas, but subsequently allowed their IND with the FDA to lapse for strategic reasons. This required us to obtain a new IND for Berubicin before beginning further clinical trials. On December 17, 2020, we announced that our IND application with the FDA for Berubicin for the treatment of Glioblastoma Multiforme was in effect. We initiated this trial for patient enrollment during the second quarter of 2021 with the first patient dosed during the third quarter of 2021 to investigate the safety and efficacy of Berubicin in adults with Glioblastoma Multiforme who have failed first-line therapy. The first patient on the trial was treated during the third quarter of 2021. Correspondence between the Company and the FDA resulted in modifications to our initial trial design, including designating overall survival (OS) as the primary endpoint of the study. OS is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. **A** **A** The current trial being conducted will evaluate the safety and efficacy of Berubicin in patients with Glioblastoma Multiforme who have failed primary treatment for their disease, and results will be compared to the safety and efficacy of Lomustine, a current standard of care in this setting, with a 2 to 1 randomization of the 252 patients to Berubicin or Lomustine. Patients receiving Berubicin are administered a 2-hour IV infusion of 7.5 mg/m² berubicin hydrochloride daily for three consecutive days followed by 18 days off (a 21-day cycle). Lomustine is administered orally once every six weeks. The trial design included a pre-planned, non-binding interim futility analysis. We reached the criteria required by the study protocol to conduct this interim futility analysis, which an independent Data Safety Monitoring Board (aDSMB) is responsible for conducting. The DSMB's charter mandated that they review the primary endpoint, Overall Survival, as well as secondary endpoints and safety data to determine whether the efficacy data for the risk-benefit profile warrants modification or discontinuation of the study. On December 18, 2023, we released the DSMB's recommendation which was to continue the study without modification. Management remains blinded to the data underlying the recommendation of the DSMB. Even if Berubicin is approved, there is no assurance that patients will choose an infusion treatment, as compared to the current standard of care, which requires oral administration. **A** We do not have manufacturing facilities and all manufacturing activities are contracted out to third parties. Additionally, we do not have a sales organization. **A** On November 21, 2017, we entered into a Collaboration and Asset Purchase Agreement with Reata (the aReata Agreement). Pursuant to the Reata Agreement we purchased all of Reata's intellectual property and development data regarding Berubicin, including all trade secrets, knowhow, confidential information and other intellectual property rights. **A** On December 28, 2017, we obtained the rights to a worldwide, exclusive royalty-bearing, license to the chemical compound commonly known as Berubicin from HPI in an agreement we refer to as the HPI License. HPI is affiliated with Dr. Priebe, who controls a majority of our shares. Under the HPI License we obtained the exclusive right to develop certain chemical compounds for use in the treatment of cancer anywhere in the world. In the HPI License we agreed to pay HPI: (i) development fees of \$750,000 over a three-year period beginning November 2019; (ii) a 2% royalty on net sales; (iii) a \$50,000 per year license fee; (iv) milestone payments of \$100,000 upon the commencement of a Phase II trial and \$1.0 million upon the approval of a New Drug Application (aFDA) for Berubicin; and (v) 134 shares of our common stock. The patents we licensed from HPI expired in March 2020. On May 14, 2024, the Company provided notice to HPI of its intent to terminate the HPI License effective on or about July 14, 2024. **A** **A** **A** **A** **A** **A** **A** **A** **A** On June 10, 2020, the FDA granted Orphan Drug Designation (aODD) for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of a NDA in the United States. During that period the FDA generally could not approve another product containing the same drug for the same designated indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. The ODD now constitutes our primary intellectual property protections although the Company is exploring if there are other patents that could be filed related to Berubicin to extend additional protections. **A** We believe we have obtained all rights and intellectual property necessary to develop Berubicin. As stated earlier, it is our plan to obtain additional intellectual property covering other compounds which, subject to the receipt of additional financing, may be developed into drugs for brain and other cancers. **A** On January 10, 2020, we entered into a Patent and Technology License Agreement (the aWP1244 Agreement) with the Board of Regents of The University of Texas System, an agency of the State of Texas, on behalf of the UTMDACC. Pursuant to the WP1244 Agreement, we obtained a royalty-bearing, worldwide, exclusive license to certain intellectual property rights, including patent rights, related to our portfolio of WP1244 drug technology. On April 25, 2024, UTMDACC provided notice to us if its intent to terminate the WP1244 Agreement if we fail to pay the annual maintenance fee of \$50,000, as well as \$1,300 in expenses. On May 25, 2024 the WP1244 Agreement was terminated. There are no termination penalty provisions in the Agreement. **A** Results of Operations for the Three Months Ended June 30, 2024 Compared to the Three Months Ended June 30, 2023 **A** General and Administrative Expense **A** General and administrative expense was approximately \$1,412,000 for the three months ended June 30, 2024 compared to approximately \$1,180,000 for the comparable period in 2023. The increase in general and administrative expense was mainly attributable to increases of approximately \$333,000 in legal and professional expenses, which were offset by decreases of approximately \$65,000 in marketing and advertising expenses, \$34,000 in insurance expense and \$2,000 in other expenses. **A** Research and Development Expense **A** Research and development expense was approximately \$1,117,000 for the three months ended June 30, 2024 compared to approximately \$2,846,000 for the comparable period in 2023. The decrease in research and development expenses during the period were mainly attributed to the timing of research organization (CRO) expenses related to continued progress with our potentially pivotal Phase II clinical trial of Berubicin. Our CRO expenditures are primarily for labor related to activating selected trial sites, managing patient enrollment processes, collecting and managing data from patient treatments throughout the trial, processing reimbursement to the sites for patient treatment, and assisting with necessary submissions to amend the IND. CRO expenditures are expected to continue to decline throughout the remainder of the trial as the final patients complete treatment and enter follow-up. **A** Net Loss **A** The net loss for the three months ended June 30, 2024 was approximately \$2,531,000 compared to approximately \$4,021,000 for the comparable period in 2023. The change in net loss is attributable to a decrease in CRO expenses related to continued progress with our potentially pivotal Phase II clinical trial of Berubicin, as well as decreases in legal and professional fees and other expenses. **A** **A** **A** **A** **A** **A** **A** **A** **A** Results of Operations for the Six Months Ended June 30, 2024 Compared to the Six Months Ended June 30, 2023 **A** General and Administrative Expense **A** General and administrative expense was approximately \$2,526,000 for the six months ended June 30, 2024 compared to approximately \$2,539,000 for the comparable period in 2023. The increase in general and administrative expense was mainly attributable to increases of approximately \$179,000 in legal and professional expenses, which were offset by decreases of approximately \$75,000 in stock-based compensation, \$46,000 in marketing and advertising expense and \$54,000 in insurance expense. **A** Research and Development Expense **A** Research and development expense was approximately \$3,547,000 for the six months ended June 30, 2024 compared to approximately \$6,413,000 for the comparable period in 2023. The decrease in research and development expenses during the period were mainly attributed to the timing of research organization (CRO) expenses related to continued progress with our Phase II clinical trial. Our CRO expenditures are primarily for labor related to activating selected trial sites, managing patient enrollment processes, collecting and managing data from patient treatments throughout the trial, processing reimbursement to the sites for patient treatment, and assisting with necessary submissions to amend the IND. CRO expenditures are expected to continue to decline throughout the remainder of the trial as the final patients complete treatment and enter follow-up. **A** Net Loss **A** The net loss for the six months ended June 30, 2024 was approximately \$6,076,000 compared to approximately \$8,953,000 for the comparable period in 2023. The change in net loss is attributable to a decrease in CRO expenses related to continued progress with our potentially pivotal Phase II clinical trial of Berubicin, as well as decreases in legal and professional fees and other expenses. **A** Liquidity and Capital Resources **A** On June 30, 2024, we had cash of approximately \$1,492,000 and we had a working capital deficit of approximately \$4,617,000. We fund our operations from proceeds from equity sales. **A** On January 29, 2024, we completed a public offering of (i) 44,314 shares of our common stock; (ii) pre-funded warrants to purchase 222,354 shares of common stock; (iii) Series A Warrants to purchase up to an aggregate of 266,667 shares of common stock; and (iv) Series B Warrants to purchase up to an aggregate of 266,667 shares of common stock. The combined purchase price of one share of common stock and accompanying Series A & B common warrants was \$15 and the combined purchase price of one pre-funded warrant and accompanying Series A & B common warrants was \$14.95 (with the pre-funded warrants having an exercise price of \$0.001). The closing of the sales of these securities occurred on February 1, 2024. The gross proceeds from the offering were approximately \$4.0 million, before deducting the placement agent's fees and other offering expenses. **A** On June 14, 2024, we entered into agreements with institutional investors for the sale of 336,000 shares of our common stock and pre-funded warrants to purchase 30,000 shares of common stock in lieu thereof (the aJune 14 Pre-Funded Warrants) in a registered direct offering. In a concurrent private placement, we also sold to the investors unregistered warrants to purchase up to an aggregate of 366,000 shares of common stock (the aJune 14 Common Warrants). The combined purchase price of one share of common stock (or pre-funded warrant in lieu thereof) and accompanying June 14 Common Warrant was \$3.75. The gross proceeds from the offering were approximately \$1.37 million, resulting in net proceeds, after payment of commissions and expenses, received by us of \$1,203,267. **A** On June 26, 2024, we entered into agreements with institutional investors for the sale of 568,000 shares of our common stock in a registered direct offering. In a concurrent private placement, we also sold to the investors unregistered warrants to purchase up to an aggregate of 568,000 shares of common stock (the aJune 26 Common Warrants). The combined purchase price of one share of common stock and accompanying June 26 Common Warrant was \$2.45. The gross proceeds from the offering were approximately \$1.39 million resulting in net proceeds, after payment of commissions and expenses, received by the Company of \$1,221,146. **A** On July 26, 2024, the Company entered into a Sales Agreement (the aAGP ATM Sales Agreement) with A.G.P./Alliance Global Partners (aAGP). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal, shares of the Company's common stock, par value \$0.001 per share with initial aggregate sales price of up to \$5.2 million. On July 30, 2024, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to \$25.0 million (not including the original \$5.2 million). As of August 14, 2024, the Company has sold 28,704,761 Shares pursuant to the Agreement for net proceeds of approximately \$10.5 million. **A** Our plan of operations is primarily focused on completing a clinical trial for Berubicin. Our current expectation is that our cash on hand as of the date of this filing is sufficient to fund our operations through the first quarter of 2025. We currently expect to release final top-line data for our potentially pivotal trial of Berubicin in the first half of 2025. If capital is available to fund TPI 287 clinical preparations and drug manufacturing for a potentially pivotal Phase 2 trial of TPI 287, we would need to raise an additional \$4.0 million to support near-term development of that program. The timing and costs of clinical trials are difficult to predict and trial plans may change in response to evolving circumstances and as such the foregoing estimates may prove to be inaccurate. **A** We will need to raise additional capital in the near term in order to continue to meet the Nasdaq minimum equity requirement. If we are unable to raise sufficient funds, we may be delisted by Nasdaq and we will be required to develop and implement an alternative plan to further extend payables, reduce overhead or scale back our business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful and if it is not successful we may need to cease operations entirely. **A** Summary of Cash Flows **A** Cash used in operating activities **A** Net cash used in operating activities was approximately \$4,842,000 and \$8,227,000 for the six months ended June 30, 2024 and 2023, respectively, and mainly included payments made for clinical trial preparation, officer compensation, insurance, marketing and professional fees to our consultants, attorneys and accountants. **A** Cash provided by financing activities **A** Net cash provided by financing activities was approximately \$5,785,000 for the six months ended June 30, 2024, related to the sale of common stock and exercise of warrants, which were offset by the repayment of notes payable and payment of deferred offering costs. Net cash provided by financing activities was approximately \$2,451,000 for the six months ended June 30, 2023, related to the sale of common stock and exercise of warrants, which were offset by the repayment of notes payable. **A** **A** **A** **A** **A** **A** **A** **A** **A** Off-balance Sheet Arrangements **A** As of June 30, 2024, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. **A** Purchase Commitments **A** We do not have any material commitments for capital expenditures,

[illegible]

[registrant](#)'s internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Â August 14, 2024 Â By: /s/ Christopher Downs

Â CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Â Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

Â The quarterly report on Form 10-Q for the quarter ended June 30, 2024 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Â August 14, 2024 Â By: /s/ John Climaco

Â CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Â Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)) of section 1350, chapter 63 of title 18, United States Code, the undersigned officer of CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

Â The quarterly report on Form 10-Q for the quarter ended June 30, 2024 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Â August 14, 2024 Â By: /s/ Christopher Downs

XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995512 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Nature of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Equity (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Equity (Details - Assumptions options) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Equity (Details - Warrant activity) link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Equity (Details - Restricted stock units activity) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Equity (Details - Performance units activity) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cns-20240630.cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cns-20240630.def.xml XBRL DEFINITION FILE EX-101.LAB 9 cns-20240630.lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Warrants [Member] Unvested Restricted Stock Units [Member] Unvested Performance Units [Member] Options [Member] Short-Term Debt, Type [Axis] November 2023 Note [Member] Class of Stock [Axis] Plan Name [Axis] Equity Plan 2020 [Member] Series A Warrants [Member] Series B Warrants [Member] Pre Funded Warrants [Member] Common Warrants [Member] Securities Financing Transaction [Axis] Securities Purchase Agreements [Member] Counterparty Name [Axis] Institutional Investor [Member] Common Stock Warrants [Member] Plan 2017 [Member] Plan 2020 [Member] Related and Nonrelated Parties [Axis] Ms Mahery [Member] Board Of Directors [Member] Related Party Transaction [Axis] Shareholder [Member] Award Type [Axis] Equity Option [Member] Class of Warrant or Right [Axis] Warrant Exercise Price [Member] Officers [Member] Restricted Stock Units (RSUs) [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Performance Units [Member] Stock Options [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Mr Climaco [Member] Mr Hsu Scientific Advisory Board [Member] Transaction Type [Axis] Technology Rights And Development Agreement [Member] Houston Pharm [Member] Patent And Technology License Agreement [Member] Wp 1244 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Deferred offering costs Prepaid expenses and other current assets Total current assets Noncurrent Assets: Prepaid expenses, net of current portion Property and equipment, net Total noncurrent assets Total Assets Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable and accrued expenses Notes payable Total current liabilities Total Liabilities Commitments and contingencies Stockholders' Equity (Deficit): Preferred stock, \$0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding Common stock, \$0.001 par value, 300,000,000 shares authorized and 1,443,274 and 124,306 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: General and administrative Research and development Total operating expenses Loss from operations Other income (expenses): Interest income Interest expense Total other income (expense) Net loss Loss per share - basic Loss per share - diluted Weighted average shares outstanding - basic Weighted average shares outstanding - diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Common stock issued for cash and warrants, net Common stock issued for cash and warrants, net, shares Common stock issued for cash, net Common stock issued for cash, net, shares Exercise of warrants Exercise of warrants, net, shares Stock-based compensation Adjustment related to reverse stock split Adjustment related to reverse stock split, shares Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Depreciation Gain on disposal of fixed assets Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable and accrued expenses Net cash used in operating activities Cash Flows from Financing Activities: Payments of deferred offering costs Payments on notes payable Proceeds from exercise of warrants Proceeds from sale of common stock and warrants, net Net cash provided by financing activities Net change in cash and cash equivalents Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Supplemental disclosure of non-cash investing and financing activities: Reclassification of deferred offering costs to equity pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] Note Payable Equity [Abstract] Equity Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation Liquidity and Going Concern Cash and Cash Equivalents Stock-based Compensation Restricted Stock Units (â€œRSUsâ€¢) Performance Units (â€œPSUsâ€¢) Loss Per Common Share Schedule of stock option activity Schedule of assumptions Schedule of stock warrant activity Schedule of RSUs activity Schedule of PUs activity Stockholders' Equity, Reverse Stock Split Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Cash FDIC insured amount Cash in excess of FDIC Antidilutive shares Short-term Debt [Table] Short-term Debt [Line Items] Short-term note payable Interest rate Maturity date Note payable balance Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Options outstanding, beginning balance Weighted average exercise price per share outstanding, beginning balance Options, granted Weighted average exercise price per share, granted Options, exercised Weighted average exercise price per share, exercised Options, forfeited Weighted average exercise price per share, forfeited Options, expired Weighted average exercise price per share, expired Options outstanding, ending balance Weighted average exercise price per share outstanding, ending balance Options, exercisable Weighted average exercise price per share, exercisable Fair value of common stock on measurement date Risk free interest rate Volatility Dividend yield Expected term (in years) Warrants outstanding at beginning Weighted-average exercise price per share at beginning Warrants granted Weighted-average exercise price per share granted Warrants exercised Weighted-average exercise price per share exercised Warrants forfeited Weighted-average exercise price per share forfeited Warrants expired Weighted-average exercise price per share expired Warrants outstanding at ending Weighted-average exercise price per share at ending Warrants exercisable Weighted-average exercise price per share Exercisable Non-vested at beginning Weighted-average grant date fair value non-vested at beginning RSUs granted Weighted average grant date fair value granted RSUs vested Weighted-average grant date fair value vested RSUs forfeited Weighted-average grant date fair value forfeited Non-vested at ending Weighted-average grant date fair value non-vested at ending PUs granted PUs vested Weighted average grant date fair value vested PUs forfeited Weighted average grant date fair value forfeited Stock, Class of Stock [Table] Class of Stock [Line Items] Common stock shares authorized Common stock par value Preferred stock shares authorized Preferred stock par value Common stock authorized for issuance Common stock increase Shares, Issued Share Price [custom:PurchaseOfPreferredWarrants-0] Purchase price per share [custom:PurchaseOfPreferredWarrantsExercised-0] Net proceeds from issuance or sale of equity Stock Issued During Period, Shares, New Issues Warrants to purchase Warrant per share Gross proceeds from issuance or sale of equity Shares authorized under plan Additional shares authorized under plan Options grants Options granted, weighted-average exercise price Vesting description Fair value of options granted Options granted Options issued Options vested Share based compensation expense Unrecognized compensation expense Weighted average remaining term Aggregate intrinsic value Warrant amendment agreement description Proceeds from warrant exercises Warrants exercised, shares Weighted average remaining term Restricted stock units granted, shares Restricted stock units granted, value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of shares granted, value Related Party Transaction [Table]

Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term EX-101.PRE 10 cnsnp-20240630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 14, 2024 Cover [Abstract] A A Document Type 10-Q Q Amendment Flag false A Document Quarterly Report true A Document Transition Report false A Document Period End Date Jun. 30, 2024 A Document Fiscal Period Focus Q2 A Document Fiscal Year Focus 2024 A Current Fiscal Year End Date --12-31 A Entity File Number 001-39126 A Entity Registrant Name CNS Pharmaceuticals, Inc. A Entity Central Index Key 0001729427 A Entity Tax Identification Number 82-2318545 A Entity Incorporation, State or Country Code NV A Entity Address, Address Line One 2100 West Loop South A Entity Address, Address Line Two Suite 900 A Entity Address, City or Town Houston A Entity Address, State or Province TX A Entity Address, Postal Zip Code 77027 A City Area Code 800 A Local Phone Number 946-9185 A Title of 12(b) Security Common Stock A Trading Symbol CNSP A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company true A Elected Not To Use the Extended Transition Period false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 32,146,403 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20:

810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12:

<https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquityNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance Sheets (Unaudited) (Parenthetical) \$ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Á Á Preferred stock, par value \$ 0.001 \$ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value \$ 0.001 \$ 0.001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares issued 1,443,274 124,306 Common stock, shares outstanding 1,443,274 124,306 X -DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X -DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X -DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X -DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-5>2Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X -DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X -DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X -DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X -ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Operations (Unaudited) - USD \$ 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Á Á Á General and administrative \$ 1,411,573 \$ 1,179,833 \$ 2,526,015 \$ 2,538,585 Research and development 1,116,562 2,845,553 3,546,974 6,413,312 Total operating expenses 2,528,135 4,025,386 6,072,989 8,951,897 Loss from operations (2,528,135) (4,025,386) (6,072,989) (8,951,897) Other income (expenses): Á Á Á Interest income 1,845,780 8,576,782 Interest expense (4,463) (3,650) (11,088) (9,086) Total other income (expense) (2,618) 4,152 (2,512) (1,284) Net loss \$ (2,530,753) \$ (4,021,234) \$ (6,075,501) \$ (8,953,181) Loss per share - basic \$ (6.72) \$ (22.08) \$ (154.70) Loss per share - diluted \$ (6.72) \$ (22.08) \$ (154.70) Weighted average shares outstanding - basic 376,643 77,547 275,113 57,874 Weighted average shares outstanding - diluted 376,643 77,547 275,113 57,874 X -DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X -DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -

45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1> + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income related to nonoperating activities, classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_OtherNonoperatingIncome Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Basic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Stockholders' Equity (Deficit) (Unaudited) - USD (\$) Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Beginning balance, value at Dec. 31, 2022 \$ 32 \$ 58,848,501 \$ (50,715,677) \$ 8,132,856 Beginning balance, shares at Dec. 31, 2022 32,347 A A Exercise of warrants \$ 12

balance, shares at Mar. 31, 2023 44,527 A A Common stock issued for cash, net \$ 660 1,969,094 1,969,107 Common stock issued for cash, net, shares 13,194 A A Exercise of warrants \$ 25,725,034 725,059 Exercise of warrants, net, shares 25,100 A A Stock-based compensation 289,670 289,670 Net loss (4,021,234) (4,021,234) Ending balance, value at Jun. 30, 2023 \$ 82,123,209 (59,668,858) 2,454,433 Ending balance, shares at Jun. 30, 2023 82,821 A A Beginning balance, value at Dec. 31, 2023 \$ 124,651,134,664 (69,566,903) (4,332,115) Beginning balance, shares at Dec. 31, 2023 124,306 A A Common stock issued for cash, net \$ 44 3,330,954 3,330,998 Common stock issued for cash, net, shares 44,314 A A Exercise of warrants \$ 45,123,360 12,405 Exercise of warrants, net, shares 44,774 A A Stock-based compensation 202,933 202,933 Net loss (3,544,748) (3,544,748) Ending balance, value at Mar. 31, 2024 \$ 213,68,680,911 (73,111,651) (4,430,527) Ending balance, shares at Mar. 31, 2024 213,394 A A Beginning balance, value at Dec. 31, 2023 \$ 124,651,134,664 (69,566,903) (4,332,115) Beginning balance, shares at Dec. 31, 2023 124,306 A A Net loss A A (6,075,501) Ending balance, value at Jun. 30, 2024 \$ 1,443,713,347,360 (75,642,404) (4,293,601) Ending balance, shares at Jun. 30, 2024 1,443,274 A A Beginning balance, value at Mar. 31, 2024 \$ 213,68,680,911 (73,111,651) (4,430,527) Beginning balance, shares at Mar. 31, 2024 213,394 A A Common stock issued for cash and warrants, net \$ 904 2,423,509 2,424,413 Common stock issued for cash and warrants, net, shares 904,000 A A Exercise of warrants \$ 208,8,713 8,921 Exercise of warrants, net, shares 208,260 A A Stock-based compensation 234,345 234,345 Adjustment related to reverse stock split \$ 118 (118) Adjustment related to reverse stock split, shares 117,620 A A Net loss (2,530,753) (2,530,753) Ending balance, value at Jun. 30, 2024 \$ 1,443,713,347,360 (75,642,404) (4,293,601) Ending balance, shares at Jun. 30, 2024 1,443,274 A A X - ReferencesNo definition available. + Details Name: CNSP CommonStockIssuedForCashAndWarrantsNetNamespace Prefix: CNSP Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP CommonStockIssuedForCashAndWarrantsNetSharesNamespace Prefix: CNSP Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1:

https://asc.fasb.org/1943274/2147478448/946-50-2-Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/214748008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT 3.24.2.u1 Statements of Cash Flows (Unaudited) - USD \$(6) Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash Flows from Operating Activities: 1,570 2,282 Jan on disposal of fixed assets (190) 0 Changes in operating assets and liabilities: A Prepaid expenses and other current assets (13,067) 823,073 Accounts payable and accrued expenses 807,460 (679,516) Net cash used in operating activities (4,842,450) (8,227,359) Cash Flows from Financing Activities: A Payments of deferred offering costs (16,750) 0 Payments on notes payable (177,558) (243,572) Proceeds from exercise of warrants 21,326 725,668 Proceeds from sale of common stock and warrants, net 5,958,270 1,969,107 Net cash provided by financing activities 5,785,282 2,451,203 Net change in cash and cash equivalents 942,838 (5,776,156) Cash and cash equivalents, at beginning of period 548,721 10,055,407 Cash and cash equivalents, at end of period 1,491,559 4,279,251 Supplemental disclosures of cash flow information: A Cash paid for interest 11,088 9,086 Cash paid for income taxes 0 0 Supplemental disclosure of non-cash investing and financing activities: A Reclassification of deferred offering costs to equity \$ 202,859 \$ 0 X - ReferencesNo definition available. + Details Name: CNPS ReclassificationOfDeferredOfferingCostsToEquity Namespace Prefix: CNPS_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdditionalCashFlowElementsOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17:

A (70)A 2,635.71A Outstanding, June 30, 2024A 1,551,422A \$15.03A Exercisable, June 30, 2024A 1,551,422A \$15.03A A As of June 30, 2024, the outstanding and exercisable warrants have a weighted average remaining term of 4.22 years and had no aggregate intrinsic value. A Restricted Stock Units A On April 28, 2022, the Board of Directors granted officers and employees a total of 193 Restricted Stock Units that partially vest over 4 years. The Company valued the RSUs based on the stock price at grant which total \$95,399. A On April 7, 2024, the Board of Directors approved grants of 5,330 RSUs to officers, employees, and board of directors. Of the 5,330 RSUs issued, 1,750 RSUs vest on the first anniversary or at the time of the 2025 shareholder meeting, whichever occurs first and 3,580 RSUs vest in 8 equal quarterly installments over 2 years. The Company valued the RSUs based on the stock price at grant which total \$69,027. A During the six months ended June 30, 2024, the Company recognized 19,566 of stock-based compensation, related to outstanding stock RSUs. At June 30, 2024, the Company had \$103,123 of unrecognized expenses related to outstanding RSUs. A The following table summarizes the RSUs activity for the six months ended June 30, 2024:

Schedule of RSUs activity	A A A RSUsA Weighted-Average Grant Date Fair Value Non-vested, December 31, 2023A A 145A A \$501.00A GrantedA A 5,330A A A 12.97A VestedA A A A A A A ForfeitedA A A A A A A Non-vested, June 30, 2024A A 5,475A A \$25.89A A Performance Units A On April 28, 2022, the Compensation Committee approved, the officers and employees were awarded a total of 573 PUs. For awards granted in 2022, they vest as follows: (i) 191 of the PU grant will vest if within 24 months from issuance the average the closing price of the Company's common stock over a ten trading day period exceeds \$3,000 (subject to pro rata adjustment for stock splits or similar events), (ii) 191 of the PU grant will vest if within 36 months from issuance the average the closing price of the Company's common stock over a ten trading day period exceeds \$6,000 (subject to pro rata adjustment for stock splits or similar events) and (iii) 191 of the PU grant will vest if within 24 months from issuance the Company achieves Positive Interim, Clinical Data as defined by the Board of Directors. To the extent that the market and/or Positive Interim Clinical Data conditions are not met, the applicable portions of the PUs will not vest and will be cancelled. The fair value at grant date of these performance units was \$169,663. Compensation expense is recognized over the derived service period for the PUs with market conditions and over the requisite service period for PUs with performance conditions on the date when achievement of such conditions are deemed probable. A The fair value of each performance unit with market conditions (vesting terms (i) and (ii)) is estimated at the date of grant using a Monte Carlo simulation with the following assumptions: underlying stock price \$501, hurdle prices ranging from \$3,000 - \$6,000, expected terms ranging from 2-3 years, cost of equity 18.7% and risk-free rate of 2.8%. A During the six months ended June 30, 2024, the Company recognized \$4,963A related to outstanding stock PUs. At June 30, 2024, the Company had \$95,399 of unrecognized expenses related to PUs. A The following table summarizes the PUs activity for the six months ended June 30, 2024:
Schedule of A PUs activity	A A A PUsA Weighted-Average Grant Date Fair Value Non-vested, December 31, 2023A A 577A A \$296.82A GrantedA A A A A A A VestedA A A A A A A ForfeitedA A A A A A A Non-vested, June 30, 2024A A 577A A \$296.82A X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies Note 5 A Commitments and Contingencies A Executive Employment Agreements A On September 1, 2017, the Company entered into an employment agreement with Mr. John Climaco pursuant to which Mr. Climaco agreed to serve as Chief Executive Officer and Director of the Company commencing on such date for an initial term of three years. On September 1, 2020, the Company entered into an amendment to the employment agreement with Mr. Climaco. The amendment extends the term of employment under the Employment Agreement, which was originally for a three-year period, for additional twelve-month periods, unless and until either the Company or Mr. Climaco provides written notice to the other party not less than sixty days before such anniversary date that such party is electing not to extend the term. If the Company provides notice of its election not to extend the term, Mr. Climaco may terminate his employment at any time prior to the expiration of the term by giving written notice to the Company at least thirty days prior to the effective date of termination, and upon the earlier of such effective date of termination or the expiration of the term, Mr. Climaco shall be entitled to receive the same severance benefits as are provided upon a termination of employment by the Company without cause. Pursuant to the Amendment, the severance benefits shall be twelve months of Mr. Climaco's base salary. Such severance payment shall be made in a single lump sum sixty days following the termination, provided that Mr. Climaco has executed and delivered to the Company and has not revoked a general release of the Company. Pursuant to the employment agreement, the compensation committee of the board of directors reviews the base salary payable to Mr. Climaco annually during the term of the agreement. On February 6, 2021, the compensation committee of the board of directors set Mr. Climaco's 2021 annual base salary to \$525,000. A On June 28, 2019, we entered into employment letters with Drs. Silberman and Picker. Dr. Silberman agreed to commit 50% of her time to our matters and Dr. Picker agreed to commit 25% of his time to our matters. A In March 2024, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling \$240,608 to the officers of the Company payable upon completion of a subsequent round of financing and a determination by the Board that such financing is sufficient for the Company's needs after payment of such bonus. A Scientific Advisory Board A On July 15, 2021, our Board approved the following compensation policy for the Scientific Advisory Board members. The Scientific Advisory board consisted of Dr. Waldemar Priebe, our founder, and Dr. Sigmond Hsu. Under this compensation policy, each scientific advisory board member was to receive annual cash compensation of \$68,600. As of August 25, 2022, Dr. Waldemar Priebe was no longer a member of the Scientific Advisory Board. On March 14, 2024, the Board of Directors terminated the cash compensation program for the Scientific Advisory Board. As of June 30, 2024, the Company has accrued \$177,309A related to Mr. Hsu's Scientific Advisory Board compensation. A WP744 Portfolio (Berubicin) A On November 21, 2017, the Company entered into a Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc. (Reata). Through this agreement, the Company purchased all of Reata's rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, the Company agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from the Company's first commercial sale of Berubicin plus \$10,000. Reata also agreed to collaborate with the Company on the development of Berubicin, from time to time. A On December 28, 2017, the Company entered into a Technology Rights and Development Agreement with Houston Pharmaceuticals, Inc. (HPI). HPI is affiliated with Dr

requirement, its securities would be delisted unless it requested a hearing. On February 21, 2024, the Company requested a hearing, which was held on April 18, 2024. Á On May 6, 2024, the Company received notification from the Nasdaq Hearings Panel (â€œPanelâ€) that it had granted an extension until July 15, 2024, which was extended until August 12, 2024 to demonstrate compliance with Listing Rules 5550(a)(2) and 5550(b). Á On July 5, 2024, the Company received a letter from the Nasdaq Staff notifying the Company that it had regained compliance with Bid Price Rule as a result of the closing bid price of the Companyâ€™s common stock being at \$1.00 per share or greater for the 20 consecutive business days from June 5, 2024, through July 3, 2024. Accordingly, the Company is in compliance with the Bid Price Rule. Á On August 7, 2024, the Company filed Form 8-K with the SEC indicating that as of that date, the Companyâ€™s shareholdersâ€™ equity was above the \$2.5 million continued listing equity requirement as set forth in Listing Rule 5550(b)(1). Á X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContentReference> 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 855-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/855/tableOfContentReference> 2:

the Company's peer group. (3) The Company does not expect to pay a dividend in the foreseeable future. Schedule of stock warrant activity Schedule of stock warrant activity

Warrants Weighted-Average Exercise Price Per Share Outstanding, December 31, 2023A \$ 84,832A \$ 151.65A GrantedA \$ 1,719,694A \$ 8.12A ExercisedA \$ (253,034)A \$ 13.18A ForfeitedA \$ 6A \$ 6A ExpiredA \$ (70)A \$ 2,635.71A Outstanding, June 30, 2024A \$ 1,551,422A \$ 15.03A Exercisable, June 30, 2024A \$ 1,551,422A \$ 15.03A Schedule of RSUs activity Schedule of RSUs activity

RSUs Weighted-Average Grant Date Fair Value Non-vested, December 31, 2023A \$ 145A \$ 501.00A GrantedA \$ 5,330A \$ 12.97A VestedA \$ 6A \$ 6A ForfeitedA \$ 6A \$ 6A Non-vested, June 30, 2024A \$ 5,475A \$ 25.89A Schedule of PUs activity Schedule of PUs activity

Weighted-Average Grant Date Fair Value Non-vested, December 31, 2023A \$ 577A \$ 296.82A GrantedA \$ 6A \$ 6A VestedA \$ 6A \$ 6A ForfeitedA \$ 6A \$ 6A Non-vested, June 30, 2024A \$ 577A \$ 296.82A X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to: (a) expected term of share options awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(f\)\(2\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1) + Details Name: us-gaap ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph \(c\) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of Business (Details Narrative) Jun. 04, 2024 Nov. 28, 2022 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Stockholders' Equity, Reverse Stock Split 1-for-50 1-for-30 X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Details Narrative) - USD \$ (6) Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A Cash FDIC insured amount \$ 250,000 A Cash in excess of FDIC \$ 1,241,559 A Warrants [Member] A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A Antidilutive shares 1,551,422 A Unvested Performance Units [Member] A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A Antidilutive shares 5,475 A Antidilutive shares 5,475 193 Unvested Performance Units [Member] A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A Antidilutive shares 577 577 Options [Member] A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A Antidilutive shares 12,177 2,591 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap CashFDICInsuredAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap CashUninsuredAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CNSP WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CNSP UnvestedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CNSP OptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CNSP NotePayable (Details Narrative) - USD \$ Nov. 28, 2023 Jun. 30, 2024 Dec. 31, 2023 Short-Term Debt [Line Items] A Note payable balance A \$ 123,248 \$ 300,806 November 2024 Note [Member] A Short-Term Debt [Line Items] A Short-term note payable \$ 329,571 A Interest rate 9.74% A Maturity date Oct. 08, 2024 A Note payable balance A \$ 123,248 X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2) + Details Name: us-gaap DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap ShortTermBorrowings Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap ShortTermDebtLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap ShortTermDebtTypeAxis=CNSP November2023NoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity (Details - Option activity) - Stock Options [Member] 6 Months Ended Jun. 30, 2024 \$ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A Options outstanding, beginning balance | shares 6,598 Weighted average exercise price per share outstanding, beginning balance | \$ / shares \$ 1,020.47 Options, granted | shares 5,579 Weighted average exercise price per share, granted | \$ / shares \$ 12.92 Options, exercised | shares 0 Weighted average exercise price per share, exercised | \$ / shares \$ 0 Options, forfeited | shares 0 Weighted average exercise price per share, forfeited | \$ / shares \$ 0 Options, expired | shares 0 Weighted average exercise price per share, expired | \$ / shares \$ 0 Options outstanding, ending balance | shares 12,177 Weighted average exercise price per share outstanding, ending balance | \$ / shares \$ 558.85 Options, exercisable | shares 2,495 Weighted average exercise price per share, exercisable | \$ / shares \$ 2,355.92 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

2Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardInItemNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity (Details - Warrant activity) - Warrants [Member] 6 Months Ended Jun. 30, 2024 \$ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A Warrants outstanding at beginning | shares 84,832 Weighted-average exercise price per share at beginning | \$ / shares \$ 151.65 Warrants granted | shares 1,719,694 Weighted-average exercise price per share granted | \$ / shares \$ 8.12 Warrants exercised | shares (253,034) Weighted-average exercise price per share exercised | \$ / shares \$ 13.18 Warrants forfeited | shares 0 Weighted-average exercise price per share forfeited | \$ / shares \$ 0 Warrants expired | shares (70) Weighted-average exercise price per share expired | \$ / shares \$ 2,635.71 Warrants outstanding at ending | shares 1,551,422 Weighted-average exercise price per share at ending | \$ / shares \$ 15.03 Warrants exercisable | shares 1,551,422 Weighted-average exercise price per share Exercisable | \$ / shares \$ 15.03 X - ReferencesNo definition available. + Details Name: CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: CNSP_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: CNSP_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: CNSP_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock

or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1:

25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Net number of non-option equity instruments granted to participants. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -SubTopic 10 -Topic 718 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Weighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \$3 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity (Details - Performance units activity) - Performance Units [Member] 6 Months Ended Jun. 30, 2024 \$ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] \$4 Non-vested at beginning | shares 577 Weighted-average grant date fair value non-vested at beginning | \$ / shares \$ 296.82 PUs granted | shares 0 Weighted average grant date fair value granted | \$ / shares \$ 0 PUs vested | shares 0 Weighted average grant date fair value non-vested at ending | \$ / shares \$ 0 PUs forfeited | shares 0 Weighted average grant date fair value forfeited | \$ / shares \$ 0 Non-vested at ending | shares 577 Weighted-average grant date fair value non-vested at ending | \$ / shares \$ 296.82 X - ReferencesNo definition available. + Details Name: CNSP ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice Namespace Prefix: CNSP Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: CNSP Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>-Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Net number of non-option equity instruments granted to participants. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -SubTopic 10 -Topic 718 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Weighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap AwardTypeAxis=CNSP PerformanceUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \$6 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity (Details Narrative) - USD (\$) 6 Months Ended 12 Months Ended Jun. 26, 2024 Jun. 14, 2024 Jun. 04, 2024 Apr. 30, 2024 Apr. 07, 2024 Feb. 01, 2024 Jan. 29, 2024 Jan. 18, 2022 Apr. 30, 2023 Aug. 09, 2024 May 01, 2024 Apr. 02, 2024 Dec. 31, 2023 Class of Stock [Line Items] \$1 \$2 \$3 \$4 \$5 \$6 \$7 \$8 \$9 \$10 \$11 \$12 \$13 \$14 \$15 \$16 \$17 \$18 \$19 \$20 \$21 \$22 \$23 \$24 \$25 \$26 \$27 \$28 \$29 \$30 \$31 \$32 \$33 \$34 \$35 \$36 \$37 \$38 \$39 \$40 \$41 \$42 \$43 \$44 \$45 \$46 \$47 \$48 \$49 \$50 \$51 \$52 \$53 \$54 \$55 \$56 \$57 \$58 \$59 \$60 \$61 \$62 \$63 \$64 \$65 \$66 \$67 \$68 \$69 \$70 \$71 \$72 \$73 \$74 \$75 \$76 \$77 \$78 \$79 \$80 \$81 \$82 \$83 \$84 \$85 \$86 \$87 \$88 \$89 \$90 \$91 \$92 \$93 \$94 \$95 \$96 \$97 \$98 \$99 \$100 \$101 \$102 \$103 \$104 \$105 \$106 \$107 \$108 \$109 \$110 \$111 \$112 \$113 \$114 \$115 \$116 \$117 \$118 \$119 \$120 \$121 \$122 \$123 \$124 \$125 \$126 \$127 \$128 \$129 \$130 \$131 \$132 \$133 \$134 \$135 \$136 \$137 \$138 \$139 \$140 \$141 \$142 \$143 \$144 \$145 \$146 \$147 \$148 \$149 \$150 \$151 \$152 \$153 \$154 \$155 \$156 \$157 \$158 \$159 \$160 \$161 \$162 \$163 \$164 \$165 \$166 \$167 \$168 \$169 \$170 \$171 \$172 \$173 \$174 \$175 \$176 \$177 \$178 \$179 \$180 \$181 \$182 \$183 \$184 \$185 \$186 \$187 \$188 \$189 \$190 \$191 \$192 \$193 \$194 \$195 \$196 \$197 \$198 \$199 \$200 \$201 \$202 \$203 \$204 \$205 \$206 \$207 \$208 \$209 \$210 \$211 \$212 \$213 \$214 \$215 \$216 \$217 \$218 \$219 \$220 \$221 \$222 \$223 \$224 \$225 \$226 \$227 \$228 \$229 \$230 \$231 \$232 \$233 \$234 \$235 \$236 \$237 \$238 \$239 \$240 \$241 \$242 \$243 \$244 \$245 \$246 \$247 \$248 \$249 \$250 \$251 \$252 \$253 \$254 \$255 \$256 \$257 \$258 \$259 \$260 \$261 \$262 \$263 \$264 \$265 \$266 \$267 \$268 \$269 \$270 \$271 \$272 \$273 \$274 \$275 \$276 \$277 \$278 \$279 \$280 \$281 \$282 \$283 \$284 \$285 \$286 \$287 \$288 \$289 \$290 \$291 \$292 \$293 \$294 \$295 \$296 \$297 \$298 \$299 \$300 \$301 \$302 \$303 \$304 \$305 \$306 \$307 \$308 \$309 \$310 \$311 \$312 \$313 \$314 \$315 \$316 \$317 \$318 \$319 \$320 \$321 \$322 \$323 \$324 \$325 \$326 \$327 \$328 \$329 \$330 \$331 \$332 \$333 \$334 \$335 \$336 \$337 \$338 \$339 \$340 \$341 \$342 \$343 \$344 \$345 \$346 \$347 \$348 \$349 \$350 \$351 \$352 \$353 \$354 \$355 \$356 \$357 \$358 \$359 \$360 \$361 \$362 \$363 \$364 \$365 \$366 \$367 \$368 \$369 \$370 \$371 \$372 \$373 \$374 \$375 \$376 \$377 \$378 \$379 \$380 \$381 \$382 \$383 \$384 \$385 \$386 \$387 \$388 \$389 \$390 \$391 \$392 \$393 \$394 \$395 \$396 \$397 \$398 \$399 \$400 \$401 \$402 \$403 \$404 \$405 \$406 \$407 \$408 \$409 \$410 \$411 \$412 \$413 \$414 \$415 \$416 \$417 \$418 \$419 \$420 \$421 \$422 \$423 \$424 \$425 \$426 \$427 \$428 \$429 \$430 \$431 \$432 \$433 \$434 \$435 \$436 \$437 \$438 \$439 \$440 \$441 \$442 \$443 \$444 \$445 \$446 \$447 \$448 \$449 \$450 \$451 \$452 \$453 \$454 \$455 \$456 \$457 \$458 \$459 \$460 \$461 \$462 \$463 \$464 \$465 \$466 \$467 \$468 \$469 \$470 \$471 \$472 \$473 \$474 \$475 \$476 \$477 \$478 \$479 \$480 \$481 \$482 \$483 \$484 \$485 \$486 \$487 \$488 \$489 \$490 \$491 \$492 \$493 \$494 \$495 \$496 \$497 \$498 \$499 \$500 \$501 \$502 \$503 \$504 \$505 \$506 \$507 \$508 \$509 \$510 \$511 \$512 \$513 \$514 \$515 \$516 \$517 \$518 \$519 \$520 \$521 \$522 \$523 \$524 \$525 \$526 \$527 \$528 \$529 \$530 \$531 \$532 \$533 \$534 \$535 \$536 \$537 \$538 \$539 \$540 \$541 \$542 \$543 \$544 \$545 \$546 \$547 \$548 \$549 \$550 \$551 \$552 \$553 \$554 \$555 \$556 \$557 \$558 \$559 \$560 \$561 \$562 \$563 \$564 \$565 \$566 \$567 \$568 \$569 \$570 \$571 \$572 \$573 \$574 \$575 \$576 \$577 \$578 \$579 \$580 \$581 \$582 \$583 \$584 \$585 \$586 \$587 \$588 \$589 \$590 \$591 \$592 \$593 \$594 \$595 \$596 \$597 \$598 \$599 \$600 \$601 \$602 \$603 \$604 \$605 \$606 \$607 \$608 \$609 \$610 \$611 \$612 \$613 \$614 \$615 \$616 \$617 \$618 \$619 \$620 \$621 \$622 \$623 \$624 \$625 \$626 \$627 \$628 \$629 \$630 \$631 \$632 \$633 \$634 \$635 \$636 \$637 \$638 \$639 \$640 \$641 \$642 \$643 \$644 \$645 \$646 \$647 \$648 \$649 \$650 \$651 \$652 \$653 \$654 \$655 \$656 \$657 \$658 \$659 \$660 \$661 \$662 \$663 \$664 \$665 \$666 \$667 \$668 \$669 \$670 \$671 \$672 \$673 \$674 \$675 \$676 \$677 \$678 \$679 \$680 \$681 \$682 \$683 \$684 \$685 \$686 \$687 \$688 \$689 \$690 \$691 \$692 \$693 \$694 \$695 \$696 \$697 \$698 \$699 \$700 \$701 \$702 \$703 \$704 \$705 \$706 \$707 \$708 \$709 \$710 \$711 \$712 \$713 \$714 \$715 \$716 \$717 \$718 \$719 \$720 \$721 \$722 \$723 \$724 \$725 \$726 \$727 \$728 \$729 \$730 \$731 \$732 \$733 \$734 \$735 \$736 \$737 \$738 \$739 \$740 \$741 \$742 \$743 \$744 \$745 \$746 \$747 \$748 \$749 \$750 \$751 \$752 \$753 \$754 \$755 \$756 \$757 \$758 \$759 \$760 \$761 \$762 \$763 \$764 \$765 \$766 \$767 \$768 \$769 \$770 \$771 \$772 \$773 \$774 \$775 \$776 \$777 \$778 \$779 \$780 \$781 \$782 \$783 \$784 \$785 \$786 \$787 \$788 \$789 \$790 \$791 \$792 \$793 \$794 \$795 \$796 \$797 \$798 \$799 \$800 \$801 \$802 \$803 \$804 \$805 \$806 \$807 \$808 \$809 \$810 \$811 \$812 \$813 \$814 \$815 \$816 \$817 \$818 \$819 \$820 \$821 \$822 \$823 \$824 \$825 \$826 \$827 \$828 \$829 \$830 \$831 \$832 \$833 \$834 \$835 \$836 \$837 \$838 \$839 \$840 \$841 \$842 \$843 \$844 \$845 \$846 \$847 \$848 \$849 \$850 \$851 \$852 \$853 \$854 \$855 \$856 \$857 \$858 \$859 \$860 \$861 \$862 \$863 \$864 \$865 \$866 \$867 \$868 \$869 \$870 \$871 \$872 \$873 \$874 \$875 \$876 \$877 \$878 \$879 \$880 \$881 \$882 \$883 \$884 \$885 \$886 \$887 \$888 \$889 \$890 \$891 \$892 \$893 \$894 \$895 \$896 \$897 \$898 \$899 \$900 \$901 \$902 \$903 \$904 \$905 \$906 \$907 \$908 \$909 \$910 \$911 \$912 \$913 \$914 \$915 \$916 \$917 \$918 \$919 \$920 \$921 \$922 \$923 \$924 \$925 \$926 \$927 \$928 \$929 \$930 \$931 \$932 \$933 \$934 \$935 \$936 \$937 \$938 \$939 \$940 \$941 \$942 \$943 \$944 \$945 \$946 \$947 \$948 \$949 \$950 \$951 \$952 \$953 \$954 \$955 \$956 \$957 \$958 \$959 \$960 \$961 \$962 \$963 \$964 \$965 \$966 \$967 \$968 \$969 \$970 \$971 \$972 \$973 \$974 \$975 \$976 \$977 \$978 \$979 \$980 \$981 \$982 \$983 \$984 \$985 \$986 \$987 \$988 \$989 \$990 \$991 \$992 \$993 \$994 \$995 \$996 \$997 \$998 \$999 \$1000 \$1001 \$1002 \$1003 \$1004 \$1005 \$1006 \$1007 \$1008 \$

A Class of Stock [Line Items] A A A A A A A A A A Options granted, weighted-average exercise price A A A A \$ 12.93 A A \$ 12.65 A A A A A Fair value of options granted A A A A \$ 58,335 A A \$ 2,728 A A A A A A A A Options granted A A A A 5,330 A A A A A A A A Options issued A A A A 5,330 A A A A A A A A Options vested A A A A 3,580 A A A A A A A A Board Of Directors [Member] | Restricted Stock Units (RSUs) [Member] A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A Fair value of options granted A A A A \$ 69,027 A A A A A A A A Options granted A A A A 5,330 A A A A A A A A Options issued A A A A 5,330 A A A A A A A A Board Of Directors [Member] | Shareholder [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A Options vested A A A A 1,750 A A A A A A A A Officers [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A Restricted stock units granted, shares A A A A 193 A A A A Restricted stock units granted, value A A A A A A A A \$ 95,399 A A A A A Equity Plan 2020 [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A Common stock par value A A A A \$ 0.001 A A A A A A A A Common stock authorized for issuance A A A A 86,916 A A A A A A A A Common stock increase A A A A 70,000 A A A A A A A A A A Plan 2017 [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A Shares authorized under plan A A A A A A A A A A 1,334 A A A A A Options granted A A A A A A A A 0 A A A A Aggregate intrinsic value A A A A A A A A \$ 0 A A A A A A A A Plan 2020 [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A Shares authorized under plan A A A A A A A A A A 2,000 A A A A Additional shares authorized under plan A A A A A A A A A A 14,916 A A A A A Options granted A A A A A A A A A A 69,973 A A A A A Common Stock [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A Common stock shares authorized A A A A A A A A A A A A A A 75,000,000 A A A A Common stock par value A A A A A A A A \$ 0.001 A A A A A Common Stock [Member] | Securities Purchase Agreements [Member] | Institutional Investor [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A Stock Issued During Period, Shares, New Issues 568,000 336,000 A A A A A A A A A A Series A Warrants [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A A A A A A A [custom:PurchaseOfPrefundedWarrants-0] A A A A A A 266,667 A A A A A Series B Warrants [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A A A A A A A [custom:PurchaseOfPrefundedWarrants-0] A A A A A A 266,667 A A A A A A A A A A Pre Funded Warrants [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A A A A A A A Purchase price per share A A A A A A \$ 15.00 A A A A A A A A Pre Funded Warrants [Member] | Securities Purchase Agreements [Member] | Institutional Investor [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A Net proceeds from issuance or sale of equity \$ 1,221,154 \$ 1,203,259 A A A A A A A A A A Warrants to purchase A 30,000 A A A A A A A A A A Warrant per share \$ 2.32 \$ 0.001 A A A A A A A A A A A A A A Gross proceeds from issuance or sale of equity \$ 1,390,000 \$ 1,370,000 A A A A A A A A A A A A A A Common Warrants [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A Purchase price per share A A A A A \$ 14.95 A A A A A A A A A A Common Stock Warrants [Member] | Securities Purchase Agreements [Member] | Institutional Investor [Member] A A A A A A A A A A A A A A Class of Stock [Line Items] A A A A A A A A A A A A A A Purchase price per share \$ 2.45 \$ 3.75 A A A A A A A A A A A A A A Warrants to purchase 568,000 366,000 A A A A A A A A A A X - References No definition available. + Details Name: CNSP_FairValueOfOptionsGranted Namespace Prefix: CNSP_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: CNSP_GrossProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: CNSP_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_PurchaseOfPrefundedWarrants Namespace Prefix: CNSP_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: CNSP_PurchaseOfPrefundedWarrantsExercised Namespace Prefix: CNSP_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: CNSP_PurchasePricePerShare Namespace Prefix: CNSP_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: CNSP_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriodTotalFairValue Namespace Prefix: CNSP_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_WarrantAmendmentAgreementDescription Namespace Prefix: CNSP_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_WarrantsExercised Namespace Prefix: CNSP_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_WarrantsIssuedShares Namespace Prefix: CNSP_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionOther than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherShareIncreaseDecrease Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareIssuedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=CNSP_WarrantExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=CNSP_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=CNSP_PerformanceUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=CNSP_BoardOfDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNSP_MsMaheryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=CNSP_BoardOfDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CNSP_ShareholderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=CNSPOfficersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=CNSP_EquityPlan2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=CNSP_Plan2017Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=CNSP_Plan2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=CNSP_SecuritiesPurchaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=CNSP_InstitutionalInvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=CNSP_SeriesAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=CNSP_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=CNSP_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=CNSP_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=CNSP_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details Narrative) - USD (\$ 6 Months Ended Aug. 07, 2024 Aug. 17, 2023 Feb. 06, 2021 Jun. 30, 2024 Jun. 30, 2023 Jul. 05, 2024 Mar. 31, 2024 Related Party Transaction [Line Items] Á Á Á Á Á Shareholders' equity Á \$ 2,500,000 Á Á Á Á Subsequent Event [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Shareholders' equity \$ 2,500,000 Á Á Á Á Subsequent Event [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Closing bid price per share Á Á Á Á \$ 1.00 Á Officers [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Cash bonuses approved Á Á Á Á Á \$ 240,608 Mr Hsu Scientific Advisory Board [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Accrued expenses related to compensation Á Á Á \$ 177,309 Á Á Houston Pharm [Member] Technology Rights And Development Agreement [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Royalty income, nonoperating Á Á \$ 25,000 Á Á Wp 1244 [Member] Patent And Technology License Agreement [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Other Nonoperating Expense Á Á \$ 1,994 \$ 27,341 Á Mr Climaco [Member] Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Annual base salary Á Á \$ 525,000 Á Á X - ReferencesNo definition available. + Details Name: CNSP_AnnualBaseSalary Namespace Prefix: CNSP_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: CNSP_ClosingBidPricePerShare Namespace Prefix: CNSP_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2 + Details Name: us-gaap_DeferredCompensationLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of expense related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAncillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyIncomeNonoperating Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThis element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. + ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityOther Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=CNSPOfficersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

[illegible]

[illegible]

[illegible]

Accounting Policies (Details Narrative) Details http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies Policies 18 false false R19.htm 995522 - Disclosure - Note Payable (Details Narrative) Sheet http://cnspharma.com/role/NotePayableDetails Narrative Note Payable (Details Narrative) Details http://cnspharma.com/role/NotePayable 19 false false R20.htm 995523 - Disclosure - Equity (Details - Option activity) Sheet http://cnspharma.com/role/EquityDetails Option Activity Equity (Details - Option activity) Details http://cnspharma.com/role/EquityTables 20 false false R21.htm 995524 - Disclosure - Equity (Details - Assumptions options) Sheet http://cnspharma.com/role/EquityDetails Assumptions Options Equity (Details - Assumptions options) Details http://cnspharma.com/role/EquityTables 21 false false R22.htm 995525 - Disclosure - Equity (Details - Warrant activity) Sheet http://cnspharma.com/role/EquityDetails Warrant Activity Equity (Details - Warrant activity) Details http://cnspharma.com/role/EquityTables 22 false false R23.htm 995526 - Disclosure - Equity (Details - Restricted stock units activity) Sheet http://cnspharma.com/role/EquityDetails Restricted Stock Units Activity Equity (Details - Restricted stock units activity) Details http://cnspharma.com/role/EquityTables 23 false false R24.htm 995527 - Disclosure - Equity (Details - Performance units activity) Sheet http://cnspharma.com/role/EquityDetails Performance Units Activity Equity (Details - Performance units activity) Details http://cnspharma.com/role/EquityTables 24 false false R25.htm 995528 - Disclosure - Equity (Details Narrative) Sheet http://cnspharma.com/role/EquityDetails Narrative Equity (Details Narrative) Details http://cnspharma.com/role/EquityTables 25 false false R26.htm 995529 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://cnspharma.com/role/CommitmentsAndContingencies Details Narrative Commitments and Contingencies (Details Narrative) Details http://cnspharma.com/role/CommitmentsAndContingencies 26 false false All Reports Book All Reports cns i10q-063024.htm cnsnp-20240630 cal.xml cnsnp-20240630 def.xml cnsnp-20240630 lab.xml cnsnp-20240630 pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/ecd/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 44 MetaLinks json IDEA: XBRL DOCUMENT CENSFP { "version": "2.2", "instance": { "cns i10q-063024.htm": { "nsprefix": "CNSP", "nsuri": "http://cnspharma.com/20240630", "dts": { "inline": { "local": { "cns i10q-063024.htm" } }, "schema": { "local": { "cnsnp-20240630.xml" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/rr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/rr/role/net-2009-12-16.xsd", "http://www.xbrl.org/rr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/role/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/role/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/str/2024/str-2024.xsd" }, "calculationLink": { "local": { "cnsnp-20240630 cal.xml" } }, "definitionLink": { "local": { "cnsnp-20240630 def.xml" } }, "labelLink": { "local": { "cnsnp-20240630 lab.xml" } }, "presentationLink": { "local": { "cnsnp-20240630 pre.xml" } } }, "keyStandard": 22, "axisCustom": 22, "axisStandard": 15, "axisCustom": 0, "memberStandard": 10, "memberCustom": 28, "hidden": { "total": 32, "http://fasb.org/us-gaap/2024": 26, "http://cnspharma.com/20240630": 1, "http://xbrl.sec.gov/ecd/2024": 5, "contextCustom": 124, "entityCustom": 1, "segmentCustom": 41, "elementCustom": 403, "unitCustom": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 374, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4, "report": { "R1": { "role": "http://cnspharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "p", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "p", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R2": { "role": "http://cnspharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Balance Sheets (Unaudited)", "shortName": "Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R3": { "role": "http://cnspharma.com/role/BalanceSheetsParentetical", "longName": "00000003 - Statement - Balance Sheets (Unaudited) (Parentetical)", "shortName": "Balance Sheets (Unaudited) (Parentetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPSHares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span", "span", "span", "span", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R4": { "role": "http://cnspharma.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Statements of Operations (Unaudited)", "shortName": "Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R5": { "role": "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit", "longName": "00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2024-12-31 us-gaap CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "span", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-03-31 us-gaap CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "span", "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R6": { "role": "http://cnspharma.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Statements of Cash Flows (Unaudited)", "shortName": "Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": 0, "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading

31_custom_StockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_StockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R21": { "role": "http://cnspharma.com/role/EquityDetailsAssumptionsOptions", "longName": "995524 - Disclosure - Equity (Details - Assumptions options)", "shortName": "Equity (Details - Assumptions options)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "CNSP:FairValueOfCommonStockOnMeasurementDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "CNSP:FairValueOfCommonStockOnMeasurementDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R22": { "role": "http://cnspharma.com/role/EquityDetails-WarrantActivity", "longName": "995525 - Disclosure - Equity (Details - Warrant activity)", "shortName": "Equity (Details - Warrant activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R23": { "role": "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "longName": "995526 - Disclosure - Equity (Details - Restricted stock units activity)", "shortName": "Equity (Details - Restricted stock units activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R24": { "role": "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "longName": "995527 - Disclosure - Equity (Details - Performance units activity)", "shortName": "Equity (Details - Performance units activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_PerformanceUnitsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "R25": { "role": "http://cnspharma.com/role/EquityDetailsNarrative", "longName": "995528 - Disclosure - Equity (Details Narrative)", "shortName": "Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-01", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "unique": true }, "R26": { "role": "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995529 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2023-08-16to2023-08-17", "name": "us-gaap:StockholdersEquityOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-08-16to2023-08-17", "name": "us-gaap:StockholdersEquityOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "cns i10q-063024.htm", "first": true, "unique": true }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } }, "auth_ref": ["r33", "r34"] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": { "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Cash bonuses approved", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } }, "auth_ref": ["r34"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } }, "auth_ref": ["r467"] }, "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract", "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } }, "auth_ref": ["r43", "r407", "r585"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } }, "auth_ref": ["r305", "r517", "r518", "r519", "r520", "r568", "r586"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } }, "auth_ref": ["r473"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } }, "auth_ref": ["r473"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } }, "auth_ref": ["r473"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote" } }, "auth_ref": ["r473"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } }, "auth_ref": ["r28", "r29", "r191"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": { "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Adjustment related to reverse stock split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } }, "auth_ref": ["r5", "r66"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities." } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } }, "auth_ref": ["r438", "r449", "r459", "r484"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } }, "auth_ref": ["r441", "r452", "r462", "r487"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "auth_ref": ["r473"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "auth_ref": ["r480"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "auth_ref": ["r442", "r453", "r463", "r480", "r488", "r492", "r500"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } }, "auth_ref": [] }, "CNSP_AnnualBaseSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "AnnualBaseSalary", "crdr": "debit", "presentation": { "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Annual base salary" } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } }, "auth_ref": ["r445"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Antidilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } }, "auth_ref": ["r134"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-

gaap/2024". "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"]. "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r15"] }, "us-gaap Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets [Default Label]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r74", "r80", "r89", "r109", "r137", "r141", "r143", "r144", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r238", "r240", "r253", "r279", "r339", "r396", "r397", "r407", "r419", "r537", "r538", "r574"] }, "us-gaap AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0 } } }, "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r86", "r94", "r109", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r238", "r240", "r253", "r407", "r537", "r538", "r574"] }, "us-gaap AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "label": "Current Assets", "documentation": "Current assets." } } }, "auth_ref": [] }, "us-gaap AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 2.0 } } }, "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r109", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r238", "r240", "r253", "r537", "r538", "r574"] }, "us-gaap AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "label": "Noncurrent Assets", "documentation": "Noncurrent assets." } } }, "auth_ref": [] }, "dei AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://cnspharma.com/role/Cover"]. "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r445"] }, "ecd AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Exercise Price", "documentation": "Exercise price." } } }, "auth_ref": ["r495"] }, "ecd AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date", "documentation": "Fair value as of grant date." } } }, "auth_ref": ["r496"] }, "ecd AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": ["r491"] }, "ecd AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered", "documentation": "Award timing method." } } }, "auth_ref": ["r491"] }, "ecd AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Award Timing Method", "documentation": "Award timing method." } } }, "auth_ref": ["r491"] }, "ecd AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered", "documentation": "Award timing MNPI considered." } } }, "auth_ref": ["r491"] }, "ecd AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "documentation": "Awards close in time to MNPI disclosures, individual name." } } }, "auth_ref": ["r492"] }, "ecd AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table", "documentation": "Awards close in time to MNPI disclosures, table." } } }, "auth_ref": ["r492"] }, "ecd AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]. "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table", "documentation": "Awards close in time to MNPI disclosures, table." } } }, "auth_ref": ["r492"] }, "us-gaap BasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies"]. "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "CNSP_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "BoardOfDirectorsMember", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"]. "lang": { "en-us": { "role": { "label": "Board Of Directors [Member]", "documentation": "Board of directors member." } } }, "auth_ref": [] }, "us-gaap CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 1.0 } } }, "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r12", "r88", "r389"] }, "us-gaap CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies"]. "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r13"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://cnspharma.com/role/StatementsOfCashFlows"]. "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents, at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r12", "r54", "r106"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": ["http://cnspharma.com/role/StatementsOfCashFlows"]. "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r54"] }, "us-gaap CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"]. "lang": { "en-us": { "role": { "label": "Cash FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"]. "lang": { "en-us": { "role": { "label": "Cash in excess of FDIC", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ecd ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"]. "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote", "documentation": "Changed peer group, footnote." } } }, "auth_ref": ["r471"] }, "dei CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://cnspharma.com/role/Cover"]. "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city." } } }, "auth_ref": [] }, "us-gaap ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"]. "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r83", "r91", "r92", "r93", "r109", "r128", "r129", "r131", "r133", "r139", "r140", "r146", "r156", "r158", "r159", "r160", "r163", "r164", "r169", "r170", "r173", "r176", "r183", "r253", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r327", "r348", "r368", "r379", "r380", "r381", "r382", "r383", "r508", "r515", "r521"] }, "us-gaap ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"]. "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r91", "r92", "r93", "r139", "r169", "r170", "r171", "r173", "r176", "r181", "r183", "r300", "r301", "r302", "r303", "r400", "r508", "r515"] }, "us-gaap ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"]. "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r25"] }, "us-gaap ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"]. "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://cnspharma.com/role/EquityDetails-WarrantActivity", "http://cnspharma.com/role/EquityDetailsNarrative"]. "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-average exercise price per share at beginning", "periodEndLabel": "Weighted-average exercise price per share at ending", "label": "Warrant per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r184"] }, "us-gaap ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://cnspharma.com/role/EquityDetails-WarrantActivity"]. "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding at beginning", "periodEndLabel": "Warrants outstanding at ending", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "CNSP_ClosingBidPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ClosingBidPricePerShare", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"]. "lang": { "en-us": { "role": { "label": "Closing bid price per share", "documentation": "Closing bid price per share." } } }, "auth_ref": [] }, "ecd CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"]. "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "documentation": "Company selected measure amount." } } }, "auth_ref": ["r472"] }, "ecd CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"]. "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "documentation": "Company selected measure name." } } }, "auth_ref": ["r472"] }, "us-gaap CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } } }, "presentation": ["http://cnspharma.com/role/BalanceSheets"]. "lang": { "en-us": { "role": { "label": "Commitments and

"contingencies", "documentation": "Represents title caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } }, {"auth_ref": ["r39", "r76", "r281", "r326"] }, {"us_gaap": "CommitmentsAndContingenciesDisclosureAbstract", "xbrl_type": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure Abstract"} } }, {"auth_ref": [] }, {"us_gaap": "CommitmentsAndContingenciesDisclosureTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://cnspharma.com/role/CommitmentsAndContingencies", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, {"auth_ref": ["r60", "r150", "r151", "r385", "r531", "r536"] }, {"us_gaap": "CommonStockCapitalSharesReservedForFutureIssuance", "xbrl_type": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common stock authorized for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, {"auth_ref": ["r42"] }, {"CNSP": "CommonStockIssuedForCashAndWarrantsNet", "xbrl_type": "monetaryItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonStockIssuedForCashAndWarrantsNet", "crdr": "credit", "presentation": { "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Common stock issued for cash and warrants, net" } } }, {"auth_ref": ["r1"] }, {"CNSP": "CommonStockIssuedForCashAndWarrantsNetShares", "xbrl_type": "sharesItemValueType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonStockIssuedForCashAndWarrantsNetShares", "presentation": { "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Common stock issued for cash and warrants, net shares" } } }, {"auth_ref": [] }, {"us_gaap": "CommonStockMember", "xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common stock member", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, {"auth_ref": ["r42", "r327"] }, {"us_gaap": "CommonStockSharesIssued", "xbrl_type": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://cnspharma.com/role/BalanceSheetsParentetical", "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, {"auth_ref": ["r42"] }, {"us_gaap": "CommonStockSharesOutstanding", "xbrl_type": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://cnspharma.com/role/BalanceSheetsParentetical", "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, {"auth_ref": ["r5", "r42", "r327", "r345", "r586", "r587"] }, {"us_gaap": "CommonStockValue", "xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://cnspharma.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Common stock, \$0.001 par value, 300,000,000 shares authorized and 1,443,274 and 124,306 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, {"auth_ref": ["r42", "r283", "r407"] }, {"CNSP": "CommonStockWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]" } } }, {"auth_ref": [] }, {"CNSP": "CommonWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common Warrants [Member]" } } }, {"auth_ref": [] }, {"ecdc": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure", "documentation": "Face amount or stated value per share of common stock." } } }, {"auth_ref": ["r477"] }, {"ecdc": "CompActuallyPaidVsNetIncomeTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, {"auth_ref": ["r5", "r42", "r327", "r345", "r586", "r587"] }, {"us_gaap": "CommonStockValue", "xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://cnspharma.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Common stock, \$0.001 par value, 300,000,000 shares authorized and 1,443,274 and 124,306 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, {"auth_ref": ["r42", "r283", "r407"] }, {"CNSP": "CommonStockWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]" } } }, {"auth_ref": [] }, {"CNSP": "CommonWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common Warrants [Member]" } } }, {"auth_ref": [] }, {"ecdc": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure", "documentation": "Face amount or stated value per share of common stock." } } }, {"auth_ref": ["r477"] }, {"ecdc": "CompActuallyPaidVsNetIncomeTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, {"auth_ref": ["r5", "r42", "r327", "r345", "r586", "r587"] }, {"us_gaap": "CommonStockValue", "xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://cnspharma.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Common stock, \$0.001 par value, 300,000,000 shares authorized and 1,443,274 and 124,306 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, {"auth_ref": ["r42", "r283", "r407"] }, {"CNSP": "CommonStockWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]" } } }, {"auth_ref": [] }, {"CNSP": "CommonWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "CommonWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Common Warrants [Member]" } } }, {"auth_ref": [] }, {"ecdc": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure", "documentation": "Face amount or stated value per share of common stock." } } }, {"auth_ref": ["r477"] }, {"ecdc": "CompActuallyPaidVsNetIncomeTextBlock", "xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, {"auth_ref": ["r5", "r42", "r327", "r345", "r586", "r587"] }, {"us_gaap": "CommonStockValue", "xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "debit", "calculation": { "http://cnspharma.com/role/BalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://cnspharma.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Common stock, \$0.001 par value, 300,000,000 shares authorized and 1,443,274 and 124,306 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, {"auth_ref": ["r42", "r283", "r407"] }, {"CNSP": "CommonStockWarrantsMember", "xbrl_type": "domainItemType", "nsuri": "http://cnspharma.com/20240630

"localname": "EmployeeExpenseShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [{"http://cnspharma.com/role/EquityDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."}}}, "auth_ref": ["r222"]}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name"}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number"}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park"}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, City or Town", "documentation": "Name of the City or Town"}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Address, State or Province", "documentation": "Name of the state or province."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Bankruptcy Proceedings Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Current Reporting Status", "documentation": "Indicate Yes or No whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity File Number", "documentation": "The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Small Business", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Voluntary Filers", "documentation": "Indicate Yes or No if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Entity Well Known Seasoned Issuer", "documentation": "Indicate Yes or No if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-O, N-1A."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Equity Abstract", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Equity Component Domain", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Equity Plan 2020 Member", "documentation": "Equity Plan 2020 Member."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Equity Valuation Assumption Difference Fn Text Block", "documentation": "Equity Valuation Assumption Difference Fn Text Block."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Equity Valuation Assumption Difference Pn Text Block", "documentation": "Equity Valuation Assumption Difference Pn Text Block."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Error Comp Analysis Text Block", "documentation": "Error Comp Analysis Text Block."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Error Comp Recovery Table", "documentation": "Error Comp Recovery Table."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Executive Category Axis", "documentation": "Executive Category Axis."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Extension", "documentation": "Extension number for local phone number."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Fair Value of Common Stock On Measurement Date", "documentation": "Fair value of common stock on measurement date."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Fair Value of Options Granted", "documentation": "Fair value of options granted."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Forgone Recovery Due To Disqualification Of Tax Benefits Amt", "documentation": "Forgone Recovery due to Disqualification of Tax Benefits Amount."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Forgone Recovery Due To Disqualification Of Tax Benefits Amt", "documentation": "Forgone Recovery due to Disqualification of Tax Benefits Amount."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Forgone Recovery Due To Expense Of Enforcement Amt", "documentation": "Forgone Recovery due to Expense of Enforcement Amount."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Forgone Recovery Due To Violation Of Home Country Law Amt", "documentation": "Forgone Recovery due to Violation of Home Country Law Amount."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Forgone Recovery Explanation Of Impracticability Text Block", "documentation": "Forgone Recovery Explanation of Impracticability Text Block."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Gain Loss On Disposition Of Assets", "documentation": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "General And Administrative Expense", "documentation": "General And Administrative Expense."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Income Statement Abstract", "documentation": "Income Statement Abstract."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Income Taxes Paid", "documentation": "Income Taxes Paid."}}}, {"http://cnspharma.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "documentation": "Increase Decrease In Accounts Payable And Accrued Liabilities."}}}]}

"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": { "r2": 1 } }, "us-gaap IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities." } } }, "auth_ref": { "us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r2": 1 } }, "ecd IndividualAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Individual Axis" } } }, "auth_ref": { "r442": "r453": "r463": "r480": "r488": "r492": "r500": 1 } }, "ecd InsiderTradingArrlInetItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrlInetItems", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrlInetItems": { "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "documentation": "Insider Trading Policies and Procedures [Line Items]", "auth_ref": { "r498": 1 } }, "ecd InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted", "documentation": "Insider Trading Policies and Procedures Adopted", "auth_ref": { "r434": "r503": 1 } }, "ecd InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted", "documentation": "Insider Trading Policies and Procedures Not Adopted", "auth_ref": { "r434": "r503": 1 } }, "CNSP InstitutionalInvestorMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "InstitutionalInvestorMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Institutional Investor [Member]", "documentation": "Institutional Investor [Member]", "auth_ref": { "us-gaap InterestExpenseNonoperating": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": { "r142": "r511": 1 } }, "us-gaap InterestPaidNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r102": "r104": "r105": 1 } }, "us-gaap Liabilities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r11": "r33": "r34": "r35": "r37": "r38": "r39": "r40": "r109": "r146": "r156": "r157": "r158": "r159": "r160": "r161": "r162": "r163": "r164": "r239": "r240": "r241": "r253": "r325": "r394": "r419": "r537": "r574": "r575": 1 } }, "us-gaap LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders' Equity (Deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r47": "r77": "r285": "r407": "r516": "r527": "r571": 1 } }, "us-gaap LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Equity (Deficit)" } } }, "auth_ref": { "us-gaap LiabilitiesCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r35": "r87": "r109": "r146": "r156": "r157": "r158": "r159": "r160": "r161": "r162": "r163": "r164": "r239": "r240": "r241": "r253": "r407": "r537": "r574": "r575": 1 } }, "us-gaap LiabilitiesCurrentAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": { "CNSP LiquidityAndGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://cnspharma.com/20240630", "localname": "LiquidityAndGoingConcernPolicyTextBlock", "presentation": { "http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern" } } }, "auth_ref": { "dei LocalPhoneNumber": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "us-gaap LongTermDebtTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": { "http://cnspharma.com/role/NotePayable": { "lang": { "en-us": { "role": { "label": "Note Payable", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": { "r61": 1 } }, "srt MaximumMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://cnspharma.com/role/EquityDetailsAssumptionsOptions": { "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Maximum [Member]", "auth_ref": { "r152": "r153": "r154": "r155": "r188": "r227": "r252": "r274": "r291": "r292": "r298": "r317": "r318": "r374": "r375": "r376": "r377": "r378": "r386": "r387": "r398": "r400": "r401": "r403": "r404": "r405": "r406": "r408": "r539": "r576": "r577": "r578": "r579": "r580": "r581": 1 } }, "ecd MeasureAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Measure [Axis]", "documentation": "Measure [Axis]", "auth_ref": { "r472": 1 } }, "ecd MeasureName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": { "r472": 1 } }, "srt MinimumMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://cnspharma.com/role/EquityDetailsAssumptionsOptions": { "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Minimum [Member]", "auth_ref": { "r152": "r153": "r154": "r155": "r188": "r227": "r252": "r274": "r291": "r292": "r298": "r317": "r318": "r374": "r375": "r376": "r377": "r378": "r386": "r387": "r398": "r400": "r401": "r403": "r404": "r405": "r408": "r539": "r576": "r577": "r578": "r579": "r580": "r581": 1 } }, "ecd MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r491": 1 } }, "CNSP MrClimacoMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "MrClimacoMember", "presentation": { "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Mr Climaco [Member]", "documentation": "Mr Climaco [Member]", "auth_ref": { "CNSP MrHsuScientificAdvisoryBoardMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "MrHsuScientificAdvisoryBoardMember", "presentation": { "http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Mr Hsu Scientific Advisory Board [Member]", "documentation": "Mr Hsu Scientific Advisory Board [Member]", "auth_ref": { "CNSP MsMaheryMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "MsMaheryMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Ms Mahery [Member]", "documentation": "Ms Mahery [Member]", "auth_ref": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": { "r499": 1 } }, "ecd NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": { "r473": 1 } }, "us-gaap NatureOfOperations": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": { "http://cnspharma.com/role/NatureOfBusiness": { "lang": { "en-us": { "role": { "label": "Nature of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": { "r81": "r82": 1 } }, "us-gaap NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a refund of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r103": 1 } }, "us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities" } } }, "auth_ref": { "us-gaap NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r54": "r55": "r57": 1 } }, "us-gaap NetIncomeLoss": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit": "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r48": "r57": "r78": "r85": "r95": "r96": "r99": "r109": "r115": "r117": "r118": "r119": "r120": "r121": "r124": "r125": "r130": "r146": "r156": "r157": "r158": "r159": "r160": "r161": "r162": "r163": "r164": "r234": "r237": "r251": "r253": "r288": "r347": "r366": "r367": "r417": "r537": 1 } }, "dei NoTradingSymbolFlag": { "xbrltype": "trueItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": { "ecd NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": { "r472": 1 } }, "ecd NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "documentation": "Non-PEO NEO Average Total Compensation Amount", "auth_ref": { "r469": 1 } }, "ecd NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r499": 1 } }, "ecd NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r499": 1 } }, "us-gaap NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities." } } }, "auth_ref": { "us-gaap NonoperatingIncomeExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cnspharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://cnspharma.com/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities that is to say, excluding major activities considered part of the normal operations of the business." } } }, "auth_ref": { "r50": 1 } }, "us-gaap NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://cnspharma.com/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Other income (expenses)." } } }, "auth_ref": { "us-gaap NotesPayableCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://cnspharma.com/role/BalanceSheets": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://cnspharma.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Notes payable", "verboseLabel": "Note payable balance", "documentation": "Sum of the

carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r33", "r34"] } } , "CNSP_November2023NoteMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "November2023NoteMember", "presentation": ["http://cnspharma.com/role/NotePayableDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "November 2023 Note [Member]" } } } , "auth_ref": [] } } , "CNSP_OfficersMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "OfficersMember", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" , "http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Officers [Member]" } } } , "auth_ref": [] } } , "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": ["http://cnspharma.com/role/StatementsOfOperations"] , "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } } , "presentation": ["http://cnspharma.com/role/StatementsOfOperations"] , "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } } , "auth_ref": [] } } , "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://cnspharma.com/role/StatementsOfOperations"] , "lang": { "en-us": { "role": { "label": "Operating expenses." } } } , "auth_ref": [] } } , "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": ["http://cnspharma.com/role/StatementsOfOperations"] , "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://cnspharma.com/role/StatementsOfOperations"] , "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } , "auth_ref": ["r79", "r395", "r522", "r523", "r524", "r525", "r526"] } } , "CNSP_OptionsMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "OptionsMember", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Options [Member]" } } } , "auth_ref": [] } } , "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } } , "auth_ref": [] } } , "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } } , "auth_ref": ["r51"] } } , "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": ["http://cnspharma.com/role/StatementsOfOperations"] , "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://cnspharma.com/role/StatementsOfOperations"] , "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } } , "auth_ref": ["r101"] } } , "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } } , "auth_ref": ["r472"] } } , "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://cnspharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\u00A7Item 17\u00A7 or \u00A7Item 18\u00A7 specified when the basis of accounting is neither US GAAP nor IFRS." } } } , "auth_ref": ["r433"] } } , "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } } , "auth_ref": ["r440", "r451", "r461", "r486"] } } , "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Compensation Amount" } } } , "auth_ref": ["r443", "r454", "r464", "r489"] } } , "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } } , "auth_ref": ["r443", "r454", "r464", "r489"] } } , "CNSP_PatentAndTechnologyLicenseAgreementMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "PatentAndTechnologyLicenseAgreementMember", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Patent And Technology License Agreement [Member]" } } } , "auth_ref": [] } } , "ecd_PayV5PerformanceDisclosureLineItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayV5PerformanceDisclosureLineItems", "auth_ref": ["r468"] } } , "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "crdr": "credit", "calculation": ["http://cnspharma.com/role/StatementsOfCashFlows"] , "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } } , "presentation": ["http://cnspharma.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "negatedLabel": "Payments of deferred offering costs", "label": "Payments for Repurchase of Initial Public Offering", "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public." } } } , "auth_ref": ["r52"] } } , "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } } , "auth_ref": ["r471"] } } , "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } } , "auth_ref": ["r471"] } } , "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } } , "auth_ref": ["r470"] } } , "ecd_PeoName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO Name" } } } , "auth_ref": ["r473"] } } , "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } } , "auth_ref": ["r469"] } } , "CNSP_PerformanceUnitsMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "PerformanceUnitsMember", "presentation": ["http://cnspharma.com/role/EquityDetailsPerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang": { "en-us": { "role": { "label": "Performance Units [Member]" } } } , "auth_ref": [] } } , "CNSP_PerformanceUnitsPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://cnspharma.com/20240630", "localname": "PerformanceUnitsPolicyTextBlock", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies"] , "lang": { "en-us": { "role": { "label": "Performance Units (\u00A7201cPUs\u00A7201d)" } } } , "auth_ref": [] } } , "CNSP_Plan2017Member": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "Plan2017Member", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Plan 2017 [Member]" } } } , "auth_ref": [] } } , "CNSP_Plan2020Member": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "Plan2020Member", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Plan 2020 [Member]" } } } , "auth_ref": [] } } , "us-gaap_PlanNameAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } } , "auth_ref": ["r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565"] } } , "us-gaap_PlanNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } } , "auth_ref": ["r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565"] } } , "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } } , "auth_ref": ["r470"] } } , "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://cnspharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } } , "auth_ref": ["r427"] } } , "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://cnspharma.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } } , "auth_ref": ["r429"] } } , "CNSP_PreFundedWarrantsMember": { "xbrltype": "domainItem", "nsuri": "http://cnspharma.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]" } } } , "auth_ref": [] } } , "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://cnspharma.com/role/BalanceSheetsParentetical", "http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } } , "auth_ref": ["r41", "r169"] } } , "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://cnspharma.com/role/BalanceSheetsParentetical", "http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } } , "auth_ref": ["r41", "r327"] } } , "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://cnspharma.com/role/BalanceSheetsParentetical"] , "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } } , "auth_ref": ["r41", "r169"] } } , "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://cnspharma.com/role/BalanceSheetsParentetical"] , "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } } , "auth_ref": ["r41", "r327", "r345", "r586", "r587"] } } , "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": ["http://cnspharma.com/role/BalanceSheets"] , "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://cnspharma.com/role/BalanceSheets"] , "lang": { "en-us": { "role": { "label": "Preferred stock, \$0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note, elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } , "auth_ref": ["r41", "r282", "r407"] } } , "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": ["http://cnspharma.com/role/BalanceSheets"] , "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } } , "presentation": ["http://cnspharma.com/role/BalanceSheets"] , "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } } , "auth_ref": ["r510"] } } , "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "calculation": ["http://cnspharma.com/role/BalanceSheets"] , "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://cnspharma.com/role/BalanceSheets"] , "lang": { "en-us": { "role": { "label": "Prepaid expenses, net of current portion", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } } , "auth_ref": ["r509"] } } , "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": ["http://cnspharma.com/role/StatementsOfCashFlows"] , "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } } , "presentation": ["http://cnspharma.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "label": "Proceeds from sale of common stock and warrants, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } } , "auth_ref": ["r1"] } } , "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Net proceeds from issuance or sale of equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } } , "auth_ref": ["r1", "r300"] } } , "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": ["http://cnspharma.com/role/StatementsOfCashFlows"] , "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } } , "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative", "http://cnspharma.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "verboseLabel": "Proceeds from warrant exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } } , "auth_ref": ["r512"] } } , "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": ["http://cnspharma.com/role/BalanceSheets"] , "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } } , "presentation": ["http://cnspharma.com/role/BalanceSheets"] , "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } } , "auth_ref": ["r4", "r263", "r277", "r287", "r407"] } } , "CNSP_PurchaseOfPrefundedWarrants": { "xbrltype": "sharesItem", "nsuri": "http://cnspharma.com/20240630", "localname": "PurchaseOfPrefundedWarrants", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Custom:PurchaseOfPrefundedWarrants-01" } } } , "auth_ref": [] } } , "CNSP_PurchaseOfPrefundedWarrantsExercised": { "xbrltype": "sharesItem", "nsuri":

"http://cnspharma.com/20240630", "localname": "PurchaseOfPreferredWarrantsExercised", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Custom:PurchaseOfPreferredWarrantsExercised-01" } } }, "auth ref": [] }, "CNSP_PurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "PurchasePricePerShare", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase price per share" } } }, "auth ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth ref": ["r468"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure Table" } } }, "auth ref": ["r468"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://cnspharma.com/role/EquityDetails-AssumptionsOptions"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } } }, "auth ref": ["r152", "r153", "r154", "r155", "r186", "r188", "r218", "r219", "r220", "r227", "r252", "r271", "r272", "r274", "r291", "r292", "r298", "r317", "r318", "r374", "r375", "r376", "r377", "r378", "r386", "r387", "r398", "r400", "r401", "r403", "r404", "r405", "r406", "r408", "r411", "r535", "r539", "r569", "r577", "r578", "r579", "r580", "r581"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://cnspharma.com/role/EquityDetails-AssumptionsOptions"], "auth ref": ["r152", "r153", "r154", "r155", "r186", "r188", "r218", "r219", "r220", "r227", "r252", "r271", "r272", "r274", "r291", "r292", "r298", "r317", "r318", "r374", "r375", "r376", "r377", "r378", "r386", "r387", "r398", "r400", "r401", "r403", "r404", "r405", "r406", "r408", "r411", "r535", "r539", "r569", "r577", "r578", "r579", "r580", "r581"] }, "CNSP_ReclassificationOfDeferredOfferingCostsToEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ReclassificationOfDeferredOfferingCostsToEquity", "crdr": "credit", "presentation": ["http://cnspharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Reclassification of deferred offering costs to equity" } } }, "auth ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth ref": ["r435", "r446", "r456", "r481"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth ref": ["r145", "r187", "r265", "r266", "r280", "r286", "r320", "r321", "r322", "r323", "r324", "r344", "r346", "r373"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth ref": ["r265", "r266", "r573"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r145", "r351", "r352", "r353"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth ref": ["r145", "r187", "r265", "r280", "r286", "r320", "r321", "r322", "r323", "r324", "r344", "r346", "r373"] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": ["http://cnspharma.com/role/StatementsOfCashFlows"], "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 }, "presentation": ["http://cnspharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payments on notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth ref": ["r53"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnspharma.com/role/EquityDetailsNarrative"], "auth ref": ["r110", "r111", "r165", "r171", "r267", "r273", "r278", "r391", "r392"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": ["http://cnspharma.com/role/StatementsOfOperations"], "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "presentation": ["http://cnspharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth ref": ["r228", "r388", "r396", "r582"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth ref": ["r436", "r447", "r457", "r482"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth ref": ["r437", "r448", "r458", "r483"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth ref": ["r444", "r455", "r465", "r490"] }, "CNSP_RestrictedStockUnitsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "RestrictedStockUnitsPolicyTextBlock", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (u201cRSUsu201d)" } } }, "auth ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": ["http://cnspharma.com/role/BalanceSheets"], "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "presentation": ["http://cnspharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth ref": ["r44", "r66", "r284", "r296", "r297", "r304", "r328", "r407"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth ref": ["r84", "r112", "r113", "r114", "r116", "r121", "r123", "r125", "r147", "r148", "r149", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r237", "r242", "r244", "r245", "r247", "r249", "r261", "r262", "r293", "r295", "r305", "r586"] }, "us-gaap_RoyaltyIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyIncomeNonoperating", "crdr": "credit", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Royalty income, nonoperating", "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth ref": ["r50"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth ref": ["r499"] }, "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth ref": ["r499"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth ref": ["r15"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth ref": ["r30", "r31", "r351", "r352", "r353"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth ref": ["r190", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r218", "r219", "r220", "r221"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://cnspharma.com/role/EquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of RSUs activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth ref": ["r69"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://cnspharma.com/role/EquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth ref": ["r8", "r9", "r69"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://cnspharma.com/role/EquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth ref": ["r72"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://cnspharma.com/role/NotePayableDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth ref": ["r33"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth ref": ["r18", "r19", "r20", "r21", "r22", "r23", "r62", "r64", "r65", "r66", "r91", "r92", "r93", "r139", "r169", "r170", "r171", "r173", "r176", "r181", "r183", "r300", "r301", "r302", "r303", "r400", "r508", "r515"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://cnspharma.com/role/EquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of stock warrant activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth ref": ["r25"] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionAxis", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth ref": ["r73"] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Measurement of financing transaction securities held." } } }, "auth ref": ["r73"] }, "CNSP_SecuritiesPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "SecuritiesPurchaseAgreementsMember", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreements [Member]" } } }, "auth ref": [] }, "dei_Security12bTitle": {

"xbrltype": "securityTitleItemTextType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r421": { "dei_Security12gTitle": { "xbrltype": "securityTitleItemTextType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": { "r425": { "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemTextType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r424": { "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemTextType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": { "http://cnspharma.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": { "r430": { "CNSP_SeriesAWarrantsMember": { "xbrltype": "domainItemTextType", "nsuri": "http://cnspharma.com/20240630", "localname": "SeriesAWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } }, "auth_ref": { "CNSP_SeriesBWarrantsMember": { "xbrltype": "domainItemTextType", "nsuri": "http://cnspharma.com/20240630", "localname": "SeriesBWarrantsMember", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]" } } }, "auth_ref": { "us_gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cnspharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "http://cnspharma.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r2": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Vesting description", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r27": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity": { "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "label": "Warrants forfeited", "verboseLabel": "RSUs forfeited", "terseLabel": "PUs forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r210": { "CNSP_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriodTotalFairValue": { "xbrltype": "monetaryItemTextType", "nsuri": "http://cnspharma.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriodTotalFairValue", "crdr": "debit", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Number of shares granted, value" } } }, "auth_ref": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "label": "Warrants granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r208": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "label": "Weighted-average exercise price per share granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r208": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity": { "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity": { "lang": { "en-us": { "role": { "periodStartLabel": "Non-vested at beginning", "periodEndLabel": "Non-vested at ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r205": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity": { "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity": { "lang": { "en-us": { "role": { "auth_ref": { "r209": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://cnspharma.com/role/EquityDetails-AssumptionsOptions": { "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": { "r219": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://cnspharma.com/role/EquityDetails-AssumptionsOptions": { "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": { "r218": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://cnspharma.com/role/EquityDetails-AssumptionsOptions": { "lang": { "en-us": { "role": { "label": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { "r220": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://cnspharma.com/role/EquityDetails-OptionActivity": { "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity": { "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r190": "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r218", "r219", "r220", "r221" } } }, "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "negatedLabel": "Warrants exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": { "r7": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "negatedLabel": "Warrants expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": { "r70": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": { "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity": { "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity": { "lang": { "en-us": { "role": { "label": "RSUs granted", "verboseLabel": "PUs granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": { "r6": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Additional shares authorized under plan", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Shares authorized under plan", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r402": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Options granted", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": { "r26": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://cnspharma.com/role/EquityDetails-OptionActivity": { "http://cnspharma.com/role/EquityDetails-WarrantActivity": { "lang": { "en-us": { "role": { "label": "Options, exercisable", "verboseLabel": "Warrants exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r199": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://cnspharma.com/role/EquityDetails-OptionActivity": { "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, exercisable", "verboseLabel": "Weighted-average exercise price per share Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r199": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": { "http://cnspharma.com/role/EquityDetails-OptionActivity": { "lang": { "en-us": { "role": { "label": "Options, expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": { "r204": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://cnspharma.com/role/EquityDetails-OptionActivity": { "lang": { "en-us": { "role": { "label": "Options, forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r203": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Options grants", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": { "r547": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://cnspharma.com/role/EquityDetails-OptionActivity": { "lang": { "en-us": { "role": { "label": "Options, granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r201": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://cnspharma.com/role/EquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r26": { "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemTextType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity"], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning balance", "periodEndLabel": "Options outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r197", "r198"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price per share outstanding, beginning balance", "periodEndLabel": "Weighted average exercise price per share outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r197", "r198"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r213"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock increase", "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan." } } }, "auth_ref": ["r26"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r26"] }, "us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations, In Period, Weighted Average Exercise Price", "documentation": "Weighted average exercise price per share, exercised." } } }, "auth_ref": ["r202"] }, "us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r204"] }, "us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r203"] }, "us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-OptionActivity", "http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, granted", "documentation": "Weighted average grant date fair value granted." } } }, "auth_ref": ["r201"] }, "CNSP ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity"], "lang": { "en-us": { "role": { "label": "Weighted-average grant date fair value vested", "documentation": "Weighted average grant date fair value vested." } } }, "auth_ref": [] }, "CNSP ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-WarrantActivity"], "lang": { "en-us": { "role": { "label": "Weighted-average exercise price per share exercised" } } }, "auth_ref": [] }, "CNSP ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity"], "lang": { "en-us": { "role": { "label": "Weighted-average exercise price per share expired", "documentation": "Weighted average grant date fair value forfeited." } } }, "auth_ref": [] }, "CNSP ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity", "http://cnspharma.com/role/EquityDetails-WarrantActivity"], "lang": { "en-us": { "role": { "label": "Weighted-average exercise price per share forfeited", "documentation": "Weighted average grant date fair value forfeited." } } }, "auth_ref": [] }, "us-gaap ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r189", "r196", "r215", "r216", "r217", "r218", "r221", "r223", "r224", "r225", "r226"] }, "us-gaap ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "presentation": ["http://cnspharma.com/role/EquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of PUs activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares." } } }, "auth_ref": ["r10"] }, "us-gaap SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://cnspharma.com/role/EquityDetails-AssumptionsOptions"], "lang": { "en-us": { "role": { "label": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r217"] }, "us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average remaining term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r26"] }, "us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://cnspharma.com/role/EquityDetails-PerformanceUnitsActivity", "http://cnspharma.com/role/EquityDetails-RestrictedStockUnitsActivity"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-average grant date fair value non-vested at beginning", "periodEndLabel": "Weighted-average grant date fair value non-vested at ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average remaining term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r71"] }, "us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "CNSP ShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://cnspharma.com/20240630", "localname": "ShareholderMember", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shareholder [Member]" } } }, "auth_ref": [] }, "us-gaap SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://cnspharma.com/role/EquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r5"] }, "us-gaap SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://cnspharma.com/role/StatementsOfStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "presentation": ["http://cnspharma.com/role/NotePayableDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-term note payable", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r32", "r75", "r407", "r583"] }, "us-gaap ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://cnspharma.com/role/NotePayableDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://cnspharma.com/role/NotePayableDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r33", "r532", "r533", "r534"] }, "us-gaap ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://cnspharma.com/role/NotePayableDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r32", "r532", "r533", "r534"] }, "us-gaap SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://cnspharma.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r58", "r107"] },

[illegible]

CNSP_UnvestedRestrictedStockUnitsMember":{"xbrltype":"domainItemType","nsuri":"http://cnspharma.com/20240630","localname":"UnvestedRestrictedStockUnitsMember"},"presentation":{"http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Unvested Restricted Stock Units [Member]"}}},"auth_ref":{"us-gaap VestingAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"VestingAxis","presentation":{"http://cnspharma.com/role/EquityDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Vesting [Axis]","documentation":"Information by vesting schedule of award under share-based payment arrangement."}}},"auth_ref":{"r540","r541","r542","r543","r544","r545","r546","r547","r548","r549","r550","r551","r552","r553","r554","r555","r556","r557","r558","r559","r560","r561","r562","r563","r564","r565"},"us-gaap VestingDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"VestingDomain","presentation":{"http://cnspharma.com/role/EquityDetailsNarrative":{"lang":{"en-us":{"role":{"documentation":"Vesting schedule of award under share-based payment arrangement."}}},"auth_ref":{"r540","r541","r542","r543","r544","r545","r546","r547","r548","r549","r550","r551","r552","r553","r554","r555","r556","r557","r558","r559","r560","r561","r562","r563","r564","r565"},"CNSP_WarrantAmendmentAgreementDescription":{"xbrltype":"stringItemType","nsuri":"http://cnspharma.com/20240630","localname":"WarrantAmendmentAgreementDescription"},"presentation":{"http://cnspharma.com/role/EquityDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Warrant amendment agreement description"}}},"auth_ref":{"CNSP_WarrantExercisePriceMember":{"xbrltype":"domainItemType","nsuri":"http://cnspharma.com/20240630","localname":"WarrantExercisePriceMember"},"presentation":{"http://cnspharma.com/role/EquityDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Warrant Exercise Price [Member]"}}},"auth_ref":{"CNSP_WarrantsExercised":{"xbrltype":"sharesItemType","nsuri":"http://cnspharma.com/20240630","localname":"WarrantsExercised"},"presentation":{"http://cnspharma.com/role/EquityDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Warrants exercised shares"}}},"auth_ref":{"CNSP_WarrantsIssuedShares":{"xbrltype":"sharesItemType","nsuri":"http://cnspharma.com/20240630","localname":"WarrantsIssuedShares"},"presentation":{"http://cnspharma.com/role/EquityDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Warrants to purchase"}}},"auth_ref":{"CNSP_WarrantsMember":{"xbrltype":"domainItemType","nsuri":"http://cnspharma.com/20240630","localname":"WarrantsMember"},"presentation":{"http://cnspharma.com/role/EquityDetails-WarrantActivity"},"http://cnspharma.com/role/EquityDetailsNarrative"},"http://cnspharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure":{"lang":{"en-us":{"role":{"label":"Warrants [Member]"}}},"auth_ref":{"us-gaap WeightedAverageNumberOFDilutedSharesOutstanding":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"WeightedAverageNumberOFDilutedSharesOutstanding"},"presentation":{"http://cnspharma.com/role/StatementsOFOperations":{"lang":{"en-us":{"role":{"label":"Weighted average shares outstanding - diluted"},"documentation":"The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."}}},"auth_ref":{"r127","r133"},"us-gaap WeightedAverageNumberOFSharesOutstandingBasic":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"WeightedAverageNumberOFSharesOutstandingBasic"},"presentation":{"http://cnspharma.com/role/StatementsOFOperations":{"lang":{"en-us":{"role":{"label":"Weighted average shares outstanding - basic"},"documentation":"Number of [basic] shares or units, after adjustment for contingently issuable shares or units or other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."}}},"auth_ref":{"r126","r133"},"CNSP_Wp1244Member":{"xbrltype":"domainItemType","nsuri":"http://cnspharma.com/20240630","localname":"Wp1244Member"},"presentation":{"http://cnspharma.com/role/CommitmentsAndContingenciesDetailsNarrative":{"lang":{"en-us":{"role":{"label":"Wp 1244 [Member]"}}},"auth_ref":{"dei WrittenCommunications":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"WrittenCommunications"},"presentation":{"http://cnspharma.com/role/Cover":{"lang":{"en-us":{"role":{"label":"Written Communications"},"documentation":"Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."}}},"auth_ref":{"r506"},"std_ref":{"r0":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"1","SubTopic":"230","Topic":"830"},"Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147477401/830-230-45-1"},"r1":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"14","Subparagraph":"(a)","SubTopic":"10","Topic":"230","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-14"},"r2":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"28","Subparagraph":"(a)","SubTopic":"10","Topic":"230","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-28"},"r3":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"28","Subparagraph":"(b)","SubTopic":"10","Topic":"230","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-28"},"r4":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"1","SubTopic":"10","Topic":"360","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482099/360-10-50-1"},"r5":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","SubTopic":"10","Topic":"505","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-2"},"r6":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","Subparagraph":"(c)(1)(iv)(01)","SubTopic":"10","Topic":"718","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r7":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","Subparagraph":"(c)(1)(iv)(02)","SubTopic":"10","Topic":"718","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r8":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","Subparagraph":"(d)","SubTopic":"10","Topic":"718","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r9":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","Subparagraph":"(e)","SubTopic":"10","Topic":"718","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r10":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Subparagraph":"(c)","Paragraph":"2","SubTopic":"10","Topic":"718","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r11":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"S99","Paragraph":"1","Subparagraph":"(SX 210.5-02(22))","SubTopic":"10","Topic":"210","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480566/210-10-S99-1"},"r12":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"230","SubTopic":"10","Section":"45","Paragraph":"4","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-4"},"r13":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"230","SubTopic":"10","Section":"50","Paragraph":"1","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482913/230-10-50-1"},"r14":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"230","SubTopic":"10","Section":"50","Paragraph":"2","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482913/230-10-50-2"},"r15":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"260","SubTopic":"10","Section":"50","Paragraph":"1","Subparagraph":"(c)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482662/260-10-50-1"},"r16":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"260","SubTopic":"10","Section":"50","Paragraph":"2","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482662/260-10-50-2"},"r17":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"360","SubTopic":"10","Section":"50","Paragraph":"1","Subparagraph":"(a)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480299/360-10-50-1"},"r18":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"505","SubTopic":"10","Section":"45","Paragraph":"2","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481142/505-10-45-2"},"r19":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"505","SubTopic":"10","Section":"50","Paragraph":"10","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-1"},"r20":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"505","SubTopic":"10","Section":"50","Paragraph":"3","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-3"},"r21":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"505","SubTopic":"10","Section":"50","Paragraph":"4","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-4"},"r22":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"505","SubTopic":"10","Section":"50","Paragraph":"5","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-5"},"r23":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"505","SubTopic":"10","Section":"50","Paragraph":"8","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-8"},"r24":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Topic":"710","SubTopic":"10","Section":"30","Paragraph":"2","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147483043/710-10-30-2"},"r25":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Account

[illegible]

[Subparagraph:](#) "(d)", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482662/260-10-50-1>", "r136": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482635/260-10-55-15](\"https://asc.fasb.org/1943274/2147482635/260-10-55-15\")" }, "r137": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482964/270-10-50-1](\"https://asc.fasb.org/1943274/2147482964/270-10-50-1\")", "r138": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483014/272-10-45-1](\"https://asc.fasb.org/1943274/2147483014/272-10-45-1\")" }, "r139": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482987/272-10-50-1](\"https://asc.fasb.org/1943274/2147482987/272-10-50-1\")" }, "r140": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482987/272-10-50-3](\"https://asc.fasb.org/1943274/2147482987/272-10-50-3\")" }, "r141": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-22](\"https://asc.fasb.org/1943274/2147482810/280-10-50-22\")" }, "r142": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-22](\"https://asc.fasb.org/1943274/2147482810/280-10-50-22\")" }, "r143": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-30](\"https://asc.fasb.org/1943274/2147482810/280-10-50-30\")" }, "r144": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-32](\"https://asc.fasb.org/1943274/2147482810/280-10-50-32\")" }, "r145": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481990/310-10-45-13](\"https://asc.fasb.org/1943274/2147481990/310-10-45-13\")" }, "r146": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481687/323-10-50-3](\"https://asc.fasb.org/1943274/2147481687/323-10-50-3\")" }, "r147": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479654/326-10-65-4](\"https://asc.fasb.org/1943274/2147479654/326-10-65-4\")" }, "r148": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479654/326-10-65-5](\"https://asc.fasb.org/1943274/2147479654/326-10-65-5\")" }, "r149": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147476166/350-60-65-1](\"https://asc.fasb.org/1943274/2147476166/350-60-65-1\")" }, "r150": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482648/440-10-50-4](\"https://asc.fasb.org/1943274/2147482648/440-10-50-4\")" }, "r151": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482648/440-10-50-4](\"https://asc.fasb.org/1943274/2147482648/440-10-50-4\")" }, "r152": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483076/450-20-50-4](\"https://asc.fasb.org/1943274/2147483076/450-20-50-4\")" }, "r153": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483076/450-20-50-9](\"https://asc.fasb.org/1943274/2147483076/450-20-50-9\")" }, "r154": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480102/450-20-S99-1](\"https://asc.fasb.org/1943274/2147480102/450-20-S99-1\")" }, "r155": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480102/450-20-S99-1](\"https://asc.fasb.org/1943274/2147480102/450-20-S99-1\")" }, "r156": { "role": "

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

SWT.M.F@6L#FR<=(.G@I2U13RV,luBjD3Y3&E:5H8X'9!+L@6NFI8 MZ>?>V/CU_ MY<9V\U\S\ S2OEF9R5\XJR.3EM\$=>=3UN3T1M0.VS\?>=>YGM?U*#N;
M@8)IN<217XU)A.#4+ZJ9+567ECTJF12>3.V.U?SGWVU.FOZH 7H18T MKZ>O\Y\H\$S:ES:KWNCI=>RUF.#+%(C.P?7&HC3&IA\$=>OC3C\ZWD?>#C\MW\$@%I\$R8_C(C/8VC)@-
W4^_U.#.N|B\F.I>ETN!!I|UO<.<@.ZJ7%B.D: M6"?QB69MB?G\#D.0.H?3/LR6?>?#07V\AW^B6j3.^YE.4&21>|8#1=?:28R.MMM.l:~54SIO54W<-M<.
K_4YE.&H|0IU@C26PM?)"HUIV\170iK\YI@T731P<B T\WXM\$ #0.GD?W9KYF9DCAI74.VBB MW^O6.F/R-9.BCD02@d8\XVIZU>?U.Y:TR<OF=0 5CYE!&%SA(E)!+B4 M
2BQ#K3A630GCF(65\$\$.6<vNS4 %VS>||4B^OD R6.A&W<@SLGIQV(LM+M<S:23>@EY->|I\$5!2T/MHN 26 (/E>CFL|PCPUi4!>(W 05H8^7A
M!<R=<H>V-G< H FX61>10I/ADM@&S.YR?87 TPM1<S<.<0XOR^P+K!|PKWKI MO5!&I<.<J)A!1GD1-Q1.S1YV(CM=>?M/Z. |W9N|FV\PFV8I&O26.KF3>I
MN@<|V?#YESOQ3628UJ3|.B\WJREB..&A8.YI2. 9&F090M3FZ7K3T"W5+KfP%< M5GIO.D:IS^?>4B:3C.'VIR7>7-R?>JZ5M7?>EY-6F@|BE|WECUQM; M1-
K\Y'W\ IJTG\XQ\U2Y2<+>GE*OU!>I&R5<~L'C\I\OM8TG9I'C9@.Tf\$ MKV1>4<~W<6&N/S\I\QY6M3?/P\$336%<OCVVVCSM1% L9_>.H(G|WP> M-SXH\$18O(G<^_<388@\$(f88-
:3?2.S.WF99OR|>=VAD7K.XS.V+?%5L73L.M\$1\$P_Y<|I|=I?M<695C?3%>OHTC<4&5+R!>+?>G_>Q\H|OR=>#.L!M1NNV-KE|U=K?2
OEFEbZ^E.R<+K.R^L4R@|O=WW7N@NOI|>|W3W&Ql8R+>%M33; MJRZT|.OCBUV*.*A:8SVZ|I|LIG7:~3&7KI378M.7O_C\YH+F.H:M.
7.SU|Y 7G JVRPV^UG=>|OJBXW0R|3J@!>2WH KIMJ\$IL7+>?42^T4!6TN4M<D=|@CUI|QOW%| MHOO3?Fb\$7FAPQI3!4LNC1H+3U5>G%>.DB
4IRZU~797%30F^<CLTIG2Y.\$i\$13>207SAL.M -=TO MOFL+>=242%-8T%Oa98#.S^V'>|U903K1(C-9E20++44L+0 #.1!^W@I2ZW MQ?2P!^5 |NFCI(<=>FB7XX3.U.#NUS!W^4?<
%>:0!|FFH|H#~RCR0VILL\$<MPR^<.&6WV=|V5.ICLK<P^&98WC%ASRO!+ 58X+HBV CK7W\LN!A>00 " MSCS58MKIVC<XIG6T!1" #.\$!>WNI912Y7@>|>ZKX4P^<CSO6N\$K9I\$S
MG>:|I&E|PW03PK|JH">3%TP/5&G\$IGE" w7 MMDK05)>XPI^~17W #.GUSO MG<TXPC&A-|IV-9+2U-CTNSA M6W\$EJO\$-1.2!P|M=11F5!>|0PNNI6VMC=V|>.%W+<TV2 M6
~<L1N!N2Y^~9JRGKEZF.ZR65NNPWK\$!4HJUTR22Y%P8PWY.LH519 MBP8B2KP2\$WAH*GT^&V9?2V+B9W13K2.PLF7IZ/L^YK.VH.U:O^C X16! 1 M|I@>ZIL26(EW-
0L.HL&ZJ.1R|I|U|Z|=K=<..|l|H7HPE|>5 HS M0<?F#F#F^AINYA\$(ZBTFCE7F:~43 +9#00 MNK/O!<+K1\$>_PLXQ9R.8I9E82.7W\$+1299FE|A!>KSCQ6Z 3.P33O?2 MX=70^<S3\$N!>H^<
(*E*IUdLO|@>|>F#>PXI3FY3Y!B\$5NW#RYZ=>#I-NIWy_MZY0'UNZP-R...HL/ZXK/SW (-:8<~:8K3S\$<R2/IH8+4I@>R?>#1B<S^X(S MWF21O(HDVMO_&J9 &*>=|U'Z|5OKMA=N^93F|
I/XTASGFL52Y2D\$>5 4 MEI+F66^YC%RZ?|C|3:Pf\$<~*W?&M2K=2>7G3VY1UO MOR9I@&CJN D=EP M6^M0|DU|RY|@>|WU|V?YAP?T?>=|>(>?>L3M8Z)&XAFZ?>#XK|:OD4
METN\$|@R4?>Y^<N@|21Y4A AO=7ZU?I9\$&M \$>?A7H<|XJOE|ODI>27J3Y+7OG 33S3L E|@I L PL>?5Y8V1"Y9WVN MH<66WU7^11+H@>P+JE5JQ4?>
*O=FALJUEZH?>1.HK3? SHS2XZ?|H.W?<M+>+>?>YL?FED0.M_9?>3&G^/J6T^K1SM^7Q2.4" P" M^>|AYV|<+>=>|V8 P1.GNIX.E#U= OF31.N7\$SKUN.:%=A3K/7KNY0!>#MX
M=7%2G|YEZ7^3H7&|&3JR 26 \$H^6AG.F8.4+1*>+>|C|>XU|(|.*%M1A 03*< M9.L>DRI@76R?M6=>=>SYLH">_./S%G6N>SAR\$FEA4P6V?LCATGS?>:13 M2?QA:S7U|U!<@450Z|3O:ZA
/M>#?1|8I2|J<..<SOA7DV.#.WDAL..|>3 M?>R@>|Y889Z78H.W8GY<8CR^T:1'G=>I'@.OISFN\$E^C">HS.6FCLQ-OK5 M#..A_l44%DY-PD#9D4/N94-&|L.W(06
N=NEFX\$ST6|l=5COEFODIE2Y6L M2.1.>D>A<ZJG074IIT>7CLH7CTH+H>L0J@>|LHJSC%HDMTI=A00A4
MR4@00>R6KWA%:%HSYE/>OBBR6K746(B<2!>?D33LR9G|I>X+P4|XPKA_ M<+K|4#9=8X&UX9I62>8WE14KE2Z/FH?I853FZ/OD0^#W L\W 8|O=>..9|D(S5X MFP^9 /4O>38C9G2?
HVK ^1|B\W.IZ.OJ| M-YD|U5Y=|4|A|EACV<U>Y..KY+T4H=>?>6M0K?>7F&|I1-NP3-E.76?2T|U> MIFI|4U9 "928 H7R2Z|7G|N7N?G|<INXW?WYN|s6^BR>S>4D>:8YXU%Y|G?>
EJ MN:6HWSPEC21O64I&X15G|C|J NZH9>QQM\$M@3:L7?V00K2|>S^>B&DX<=Z MXH-AAGV^<8>18 IR-NHZ<~*0&SOR3L3!>|I=(1%W>=>9A9%IN%6KU3!AA
MX\$<49I03U@>|MXL|@>|HIP<~@4@LZNWQ+#!I?"68H@MU">0.CRDQ.KUEDPC3 M6|YU9^*R^X S\$J KYEA>.#IWO+XMM6Y|CC+1R(2AWW?T|ZTWZSAR=Y= M
MA0\$>00%KV_Q<@.D^B1<~S2^4?>Z2-Q4R0OHF1T6^H^B@ PR^+!\$!\$U'R: MUP^+|/JEL &2I(ODA< DMZ8G7T5PO.G\$G4+X.M9.6O.9W|GEOZQ|>=24CEC/S;=T98WKN|XU#X|
|X|+W|Z|>RW>?>=<42I\$H.MO?|K.F4WC%Z%|H@>VFI|>S'L:=E.F|L\$>V08O.TLYES:IN0@QTB 2T<E.MV.7.2?>GVQOZ^!L#>=>|SNRF?>|RYN^C=>|J^3E.HYHNH?>
M^>+Q|>E.D0H.NBNO2W^B\$S1^AW65B0I?FUZK7Z2KQ<+Q+Z\$= 7P MO?>8V7Q|D19/4F+Q|Z.AMP90%Y4.W|E.U.^21C^<+K JEG95KIFF7 MMS?>^V1N|. &C^*K.0|0^/I@?>
M&=00#|J.J%3A7B).@ODULB\$Z2.IOFFPT+3#?Q:M.MPIWO|>=O W ZR2LMC MB715+1ESYV1!TNO6ZT|61SM..Y?|00T^X|&G6OU?>+>UHO\$N# X^>UZKN MO=5IPN^91O|>#?
OPY:>=>X.C74KLD?>X|SE6+39UPV@ORC=>+|I&M> 5 06M2M|>=>f:2P5Y1& 1@FJSZ%AGUB?>7?RIGKY> RJ184
MVY|8I=<M..M|>2.CLF>754FO@>GZ\$SFW57C|>9TO.6 06M6&9AB7P2D|U|H|B MP|I^+~H64 6>N7@>|05P5P|?I8L3.D2>AXUW06@&R&1K^S -H8B|W8.1N3 MJD|D|11ME.0(O|
Y3KPII3FR75WRR&+>|I+M+A.U0I3HULXJ|C?>A09+>N6\$S^V&U\$>ZJQO U|S^<O^ V\ALTNM.F E M9\$104.VX|W|Y.V9X9Y|URJ| M|I| IG>D0?BA4|OP>Z>SA2?>D?B3^9% M

[illegible]

[illegible]

3-AM&S&E&A&S&E64.642@<H&XU*301 M593F0I/OJYNN4JRDH0075+EO&L(GY&C_S_LJN:3.HBGJ.WH.L1\$2K166@>|<#F.MHUU10.051B@>|<6B7>&S.HL.D3B73DC">@<N4UD"UIGH:4VNP:1 M48R5K<U>J37Z-2?2STT0.7R"LOW"=<JW&DEQ&A0UB&U.A.LC0T"IO2PIS.M4AOTL160P"FSX&HJ+>=E.VKTI&NH%_1.P1X

 |<OTASJ6Q_1.TA&IPXZXW&8D9I_N@=<6&5&JB.G&PD_1.M0F+0F8=>=A&OR1KF2VY5T4<BPLIML2R:&OJWVH=139<QY&E+V.A/B/G/M.#%>2HS+2H1S_23+&E2H

 |<+&+R&P&O>=>S<+<I&R<+<1.FHHW7(4PVP* MVJ&S1<4&4GH4.O&1Y%_1.L4@<5ES=>B/G.#0J1<4&4&1YA0FJM7R2RZ&FV1.MP.K<B.V8U17&9<+1&1R6D72B02NFE=>=KD%

 |<O>=>I&S11>Y6">?#G&4* M10I&M1>?>2U/#C&6=UW>29J_4_IY&2V1U<W.MW9I_U2D<RJ&S&H&O&S/5I29K&B MR16HM9Q&G.HGFYV<8&16M5HVRD>?>2D>?>1&M5J&B=8IV0R1JLH0J#>|<Q22

 |<M4Z11@>=UKMT6FIE.M2Z1Y4>Y.WQ&S5Y=>XGVB&88U1Y&M4UCLYUJ>|<?<67+0&1#>M1LFW NA2<R&R&F&S95.G95F.4_1_LD@<8A12>3F3D&+54&@&6.A1#<^*M*P.1HMU2C8P

 |<H34L(1L>=>15&#&M5&R1<0TU>Y.4A9>22-9BB">M*H9 M1PNVUP<M<=<+<PYR6F13HITXZ>I&N+D<PZL<8&BZ3G5167U>Y&B<A1HRRPPO MON&P<U

 |<A0LQ1>WMTU0I0Z<N=2H4IWK>DY%<W#5&2H1F66M04Q&F&V2WM1">M+W<+<XHGTO_@G1>@M3T161<+<7.KG&F&O&@%1&M&K.B.@O M6S81)>6F

 |<H0215&E&K<J&DVU5Z&+>7AY&049K3.NR<C2<6&8UJ0D7<M=>L&Y W2<1<@<ITZJ_0I0Z1P2P&E<BVTI&WHX=>#>W8#H6G12N1PH0H

 |<M/_CG@<L.G.TW7IRV73Q3DD4V=V.W.22">P.%_K8<7/27R3%J9%&18>T>S_M6(UH47D)2B1H<@Q@3&E-C=HEN>T6)S%K5<+3F2T7H71A_K'C.COTM/A8_M@IF5BU+M+N'Z

 |<ETI1H><NDCR76R14<|<B1.C6H_1L%&12>A47T3>+<M&S.A&C<1^<H_1L>2LOV1PX_Q%|<H<G1FWC7B<=<=>H&N4+<B)Z7MY0&A_MMW_S5X19<P<L.VI=>=<L<+<@<IO9Z49I

 |<8&AVAR&F3NW2>_0<A3C<C<9_M1>1OZJY&9Q03<62E04IBF5&JCS&5=>ALP&T5_G#14=>=TJ444_2D0_4V_X+MZZCX_5K5<1L>I57P1<@V8>Y<N12H1X22>?>1Y_%>=<%&C_2)>PZ&T#

 |<M1J6R7410Q&S&E0_3%<M1K0&B<A156B7.T.WA0T02<FXQ6222%>TUKITB BQ_M1/A2+9W+K%7A1%=>~<@>N%<57VR&S2R&B2VYK<9#<H1WJ&R4U1H86Y6_M6PZ7

 |<BU4&S">P<FEJ<@<EJU+>A2D_9BK16J1P1)<@<X_4_1DN09G_U_P3V1#1 MN1=>=<X&10N258IY<K-D_&L8I<PL1#<S<CY67C1+D>=<P&R<@<H1#<1M4M@XN<=<Q&6&S.822

 |<ZNR&S&P<_OOW/NH1X5&1W3T2U"D<S0I&CH&UQ&G&20_7M3I&E#<C&U&8T63&Q%<S&1&6V21P1I(TO&A319)>20M&S+A5<O&B&EYL<@<JW.MPZDI_Z1K<M<WV_2L16LPHW?>M4F&6Y<Y+Q_

 |<IR6RZV7&7S13P2<_0F1&K&6>7V&4<=<E=>A&V1<@<J9U<Q1Z<15=>M&N_N_O_@WYICX<12&7&AMD7KZT5&SMO&H<IS12&P&CQ_1R">CH2H13Q_#>M2T5V1W/09&XO<1&#

 |<IW">+4O.6&JOMJ&FU5)HAIQ_I<PH0T%<@<8&S&M&H.882&2O<J1<@<7L&Q<@66B1B=W+4I1DU.EL.B_M<(<EJ9<3P_YA>9KH7_X24&L#110<(<F#<ED7W_>V&D8<S1+5 M8VYS<=<TR_#

 |<T_#8&S_11&8&N<@<L&U1F7W<=<@<PVDN.O&W_V_Z1WXL_D_P0I<S9 M.L.>=<@<HMEM&S5Q9_M<28<=>D10UB2P166K5_O4<@<ABB2<9+>1"K&R=>B+<F.M<M7Y?>

 |<20">QWY1W627H&9ISM">Q<KVPMD<=>=<A&L7&BQ/M<2CMU2W1R MO&GDI1W&09<Q<RZLT>4Q_ S2 ONB OS_S&H<1&8M1L&U4P>=>F&A14_HW<X<WJ<VJ>613J_M1=>11C1P

 |<W3&E&F10_Q_Y1>N07L<_D&=>P=>_1<_&S&8&N1Q&B7<8Y&SULU1>=>M5AKU1<Q<O1<Q1<M<@<2N5270.GM<=>@<1)>(DOH<1I_7_412J2>=8_MQ1<D1<L<_YOS>QRP<E1MOMQ<@<IO3K1<|

 |<D31<K&V>GIMS<U+Y<K&N<S1TBR_M1_A1>JF<O&BZ1>=>R1<WDWDNDW_V1O<A1#_Z&N<1L1_TKZ_M5%+004_YT2D&A4&=>8+S<S_?<F&C.VU<1>@<(SRES<Q&9&3A13S>O_KD413M9

 |<M1N3_O<=<O1ZP100%&5)SEM&X762C1I&QZ&S1&K&3964.O1P&S3<4%<K5<3 M4Q<Q071K1>J2V<1%#>7.4CF01&S=I121J&C1&B0IAV7W+V<W<1+5&S.IVQ0_MIOFUTT7,B4Z14*4&AVUUM

 |<CBY&S=>7.4GI<@<Z1DP&E1)>?>1M&81&8&Z&S1M15H8U1>R&S26%G&4Y1&B2L.W_PORCF<7I&V&R&8Z2M<T&M6O<X<G<NVI_V1+V2_9+0&A

 |<5M1<RV5<=>%<K&33&0&ECHO18<K7_OU311H13%>7<+>%<XH">2+8C<99TNA.K&M=>A0_98+>=>6">K&D19<GO&A1&3&3D%_K>Z&W&V&S.EJGR_S0H1AQ4DLYZ?>3W4

 |<MI&K&N0&B&W&G<@<E.GPVU<+<2B&D<ZDQJ7R1>I.CSV&R10#8<+<=>E&T5%6&S1DQ?>MV#N715&*<=>5.#<6+>JTK8>+1<SVU&K<@<ZIH&S<@<S&Y&W1_M1<(<F.H&Y&O_K<|>1>L#_B.Q&4&H1Z8

 |<#>D&S&A1X<=>C">5I">P1&6<4=>W&C&S.M02IG&PZF_T3&9&P<1H1&@<B&C&F5<S1<M&R5U&R&S&1&=<A1&HO<P&V4<=>O1H_M1L<@<AT<FIM&2_W&3.B1F3<T_MXLXZ&_O03<=<BD25_41M_2N1T

 |<#>M&X19Y1HNV&M&H&Z&R5_BQM&Z&P&V_919P&C&#<_M1XU1<=>

[illegible]

us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001729427 2023-01-01 2023-03-31 0001729427 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001729427 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001729427 us-gaap:CommonStockMember 2024-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001729427 us-gaap:RetainedEarningsMember 2024-06-30 0001729427 us-gaap:CommonStockMember 2023-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001729427 us-gaap:RetainedEarningsMember 2023-06-30 0001729427 2023-06-30 0001729427 2022-11-27 2022-11-28 0001729427 2024-06-30 2024-06-04 0001729427 CNSP:WarrantsMember 2024-01-01 2024-06-30 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001729427 CNSP:UnvestedPerformanceUnitsMember 2024-01-01 2024-06-30 0001729427 CNSP:OptionsMember 2024-01-01 2024-06-30 0001729427 CNSP:WarrantsMember 2023-01-01 2023-06-30 0001729427 CNSP:UnvestedRestrictedStockUnitsMember 2023-01-01 2023-06-30 0001729427 CNSP:UnvestedPerformanceUnitsMember 2023-01-01 2023-06-30 0001729427 CNSP:OptionsMember 2023-01-01 2023-06-30 0001729427 CNSP:November2023NoteMember 2023-11-28 0001729427 CNSP:November2023NoteMember 2023-11-27 2023-11-28 0001729427 CNSP:November2023NoteMember 2024-06-30 0001729427 us-gaap:CommonStockMember 2024-05-01 0001729427 us-gaap:CommonStockMember 2024-06-30 0001729427 2024-05-01 0001729427 CNSP:EquityPlan2020Member 2024-04-30 0001729427 CNSP:EquityPlan2020Member 2024-04-29 2024-04-30 0001729427 2024-01-29 0001729427 CNSP:SeriesAWarrantsMember 2024-01-29 0001729427 CNSP:SeriesBWarrantsMember 2024-01-29 0001729427 CNSP:PreFundedWarrantsMember 2024-01-29 0001729427 CNSP:CommonWarrantsMember 2024-01-29 0001729427 2024-04-07 0001729427 2024-01-31 2024-02-01 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember 2024-06-13 2024-06-14 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember 2024-06-14 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember CNSP:CommonStockWarrantsMember 2024-06-14 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember 2024-06-13 2024-06-14 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember 2024-06-25 2024-06-26 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember CNSP:CommonStockWarrantsMember 2024-06-26 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember 2024-06-26 0001729427 CNSP:InstitutionalInvestorMember CNSP:SecuritiesPurchaseAgreementsMember CNSP:PreFundedWarrantsMember 2024-06-25 2024-06-26 0001729427 CNSP:Plan2017Member 2024-06-30 0001729427 CNSP:Plan2020Member 2024-06-30 0001729427 CNSP:Plan2020Member 2023-08-08 2024-08-09 0001729427 CNSP:MshaheryMember 2024-01-17 2024-01-19 0001729427 CNSP:BoardOfDirectorsMember 2024-01-17 2024-01-19 0001729427 CNSP:BoardOfDirectorsMember 2024-01-17 2024-01-19 0001729427 CNSP:BoardOfDirectorsMember 2024-01-19 0001729427 CNSP:BoardOfDirectorsMember 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember 2024-04-06 2024-04-07 0001729427 CNSP:BoardOfDirectorsMember 2024-04-06 2024-04-07 0001729427 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001729427 us-gaap:StockOptionMember 2024-06-30 0001729427 2024-01-28 2024-01-29 0001729427 CNSP:WarrantExercisePriceMember 2024-01-01 2024-06-30 0001729427 CNSP:WarrantsMember 2024-01-01 2024-06-30 0001729427 CNSP:OfficersMember 2022-04-27 2022-04-28 0001729427 CNSP:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2024-04-06 2024-04-07 0001729427 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-07 0001729427 us-gaap:RestrictedStockUnitsRSUMember CNSP:BoardOfDirectorsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-07 0001729427 us-gaap:RestrictedStockUnitsRSUMember CNSP:BoardOfDirectorsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-06 2024-04-07 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001729427 CNSP:PerformanceUnitsMember 2022-04-27 2022-04-28 0001729427 CNSP:PerformanceUnitsMember 2024-01-01 2024-06-30 0001729427 CNSP:PerformanceUnitsMember 2024-06-30 0001729427 CNSP:StockOptionsMember 2023-12-31 2024-06-30 0001729427 CNSP:StockOptionsMember 2024-01-01 2024-06-30 0001729427 CNSP:StockOptionsMember 2024-06-30 0001729427 sr:MinimumMember 2024-01-01 2024-06-30 0001729427 sr:MaximumMember 2024-01-01 2024-06-30 0001729427 CNSP:WarrantsMember 2023-12-31 2024-06-30 0001729427 CNSP:WarrantsMember 2024-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 2024-06-30 0001729427 CNSP:PerformanceUnitsMember 2023-12-31 2024-06-30 0001729427 CNSP:MrClimacoMember 2021-02-05 2021-02-06 0001729427 CNSP:OfficersMember 2024-03-31 0001729427 CNSP:MrHsuScientificAdvisoryBoardMember 2024-06-30 0001729427 CNSP:HoustonPharmMember CNSP:TechnologyRightsAndDevelopmentAgreementMember 2024-01-01 2024-06-30 0001729427 CNSP:HoustonPharmMember CNSP:TechnologyRightsAndDevelopmentAgreementMember 2023-01-01 2023-06-30 0001729427 CNSP:Wp1244Member CNSP:PatentAndTechnologyLicenseAgreementMember 2023-01-01 2023-06-30 0001729427 2023-08-16 2023-08-17 0001729427 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-07-05 0001729427 us-gaap:SubsequentEventMember 2024-08-06 2024-08-07 iso4217:USD shares iso4217:USD shares pure false -12.31 2024 Q2 0001729427 10-Q true 2024-06-30 false 001-39126 CUS Pharmaceuicals, Inc. NV 82-2318545 2100 West Loop South Suite 900 Houston TX 77027 800 946-9185 Common Stock CNP NASDAQ Yes Yes Non-accelerated Filer true true false false 32146403 1491559 548721 16750 202859 637087 839590 2145396 1591170 320320 104750 3553 4933 323873 109683 2469269 1700853 6639622 5832162 123248 300806 6762870 6132968 6762870 6132968 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 300000000 300000000 1443274 1443274 124306 124306 1443 124 71347360 65134664 -75642404 -69566903 -4293601 -4432115 2469269 1700853 1411573 1179833 2526015 2538585 1116562 2845553 3546974 6413312 2528135 4025386 6072989 8951897 -2528135 -4025386 -6072989 -8951897 1845 7802 8576 7802 4463 3650 11088 9086 -2618 4152 -2512 -1284 -2530753 -4021234 -6075501 -8953181 -6.72

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_custom--UnvestedPerformanceUnitsMember z3V3lG1x5qk" title="Antidilutive shares">193 common shares, unvested performance units of 577 and options for 2,591 common shares, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 845_eus-gaap-BasisOfAccountingPolicyPolicyTextBlock zzDKC6pKfqr2" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Basis of Presentation</p><p>The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2024. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2023 included in our Form 10-K filed with the SEC on April 1, 2024 ("Form 10-K"). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 847_ecustom--LiquidityAndGoingConcernPolicyTextBlock zf0XS7YNCga" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Liquidity and Going Concern</p><p>These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 840_eus-gaap-CashAndCashEquivalentsPolicyTextBlock zA4BMN8emWta" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Cash and Cash Equivalents</p><p>The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of \$250,000. The amount in excess of the FDIC insurance as of June 30, 2024 was \$1,241,559. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 250000_1241559_c" id="xdx 842_eus-gaap-ShareBasedCompensationOptionAndIncentivePlansPolicy ztVp9lxCGMdb" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Stock-based Compensation</p><p>Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 84D_ecustom--RestrictedStockUnitsPolicyTextBlock zGst1TrMVyqq2" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Restricted Stock Units ("RSUs")</p><p>- Our RSUs vest over four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 849_ecustom--PerformanceUnitsPolicyTextBlock zNRagLeKLIW" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Performance Units ("PUs")</p><p>The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim Clinical Data as defined by the Board. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 84E_eus-gaap-EarningsPerSharePolicyTextBlock z9rcbdtYDFpe" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Loss Per Common Share</p><p>Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of June 30, 2024, the Company's potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 1,551,422 common shares, unvested restricted stock units of 5,475 common shares, unvested performance units of 577 and options for 12,177 common shares, respectively. As of June 30, 2023, the Company's potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 45,399 common shares, unvested restricted stock units of 193 common shares, unvested performance units of 577 and options for 2,591 common shares, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 804_eus-gaap-LongTermDebtTextBlock zHUUYETggpp" style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0">Note Payable</p><p></p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0"></p><p id="xdx 82A_zQcFBF5YwE">Note Payable</p><p>2023, the Company entered into a short-term note payable for an aggregate of \$329,571, bearing interest at 9.74% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on October 8, 2024. As of June 30, 2024 the Company's note payable balance was \$123,248. </p><p style="font: 10pt Times New Roman, Times, Serif, margin: 0pt 0; text-align: justify"><b

SeriesAWarrantsMember z1ur6oVv3UFH">266,667shares of Common Stock (the "Series A Warrants"); and (iv) Series B Warrants to purchase up to an aggregate of 266,667shares of Common Stock (the "Series B Warrants", and together with the Series A Warrants, the "Common Warrants"). The Common Warrants and Pre-Funded Warrants are collectively referred to herein as the ("Warrants"). The combined purchase price of one share of Common Stock and accompanying Common Warrants was \$15.00 and the combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was \$14.95. In connection with the offering, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain institutional investors that participated in the offering. As of April 1, 2024, 44,094 of the Pre-Funded Warrants have been exercised. The closing of the sales of these securities occurred on February 1, 2024. The net proceeds to the Company from the offering were \$3,331,000. After deducting the placement agents' fees and other offering expenses, <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 14, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 336,000 shares of the Company's common stock and pre-funded warrants to purchase 30,000 shares of common stock in lieu thereof (the "June 14 Pre-Funded Warrants") in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 366,000 shares of common stock (the "June 14 Common Warrants"). The combined purchase price of one share of common stock (or pre-funded warrant in lieu thereof) and accompanying June 14 Common Warrant was \$3.75. The closing of this offering and private placement occurred on June 17, 2024. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain ownership limitations, each of the June 14 Common Warrants is immediately exercisable, has an exercise price of \$3.62 per share, and expire five years from the date of issuance. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain ownership limitations, each June 14 Pre-Funded Warrant is exercisable into one share of common stock at a price per share of \$0.001 (as adjusted from time to time in accordance with the terms thereof). The gross proceeds to the Company from the offering was approximately \$1.37 million, resulting in net proceeds, after payment of commissions and expenses, received by the Company of \$1,203,259. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 26, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 568,000 shares of the Company's common stock in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 568,000 shares of common stock (the "June 26 Common Warrants"). The combined purchase price of one share of common stock and accompanying June 26 Common Warrant was \$2.45. The closing of the offering and private placement occurred on June 27, 2024 (the "Closing Date"). <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain ownership limitations, each of the June 26 Common Warrants is immediately exercisable, has an exercise price of \$2.32 per share, and expire five years from the date of issuance. The June 26 Common Warrants may only be exercised on a cashless basis if there is no registration statement registering, or a prospectus contained therein in not available for, the resale of the shares of common stock underlying the June 26 Common Warrants. The gross proceeds to the Company from the offering were approximately \$1.39 million resulting in net proceeds, after payment of commissions and expenses, received by the Company of \$1,221,154. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Text-align: justify"> Stock Options </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2017, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2017 Stock Plan (the "2017 Plan"). The 2017 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 1,334 shares of common stock. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the "2020 Plan"). The 2020 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 2,000 shares of common stock. The 2020 Plan was amended effective as of August 9, 2023, which was approved by the Company's stockholders at the Company's annual meeting on September 14, 2023. The amendment increased the 2020 Plan by 14,916 shares of common stock. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 19, 2024, the Board of Directors of the Company approved the issuance of 249 options to Ms. Mahery as compensation for her appointment to our Board of Directors. The options have a ten-year term at an exercise price of \$12.65 and vest in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was \$2,728. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 7, 2024, the Board of Directors approved grants of 5,330 options to officers, employees, and board of directors. The options have a ten-year term at an exercise price of \$12.93. Of the 5,330 options issued, 1,750 options vest on the first anniversary or at the time of the 2025 shareholder meeting, whichever occurs first and 3,580 options vest in 36 equal monthly installments over 3 years. The total fair value of these option grants at issuance was \$58,335. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended June 30, 2024 and 2023, the Company recognized \$412,749 and \$544,248 of stock-based compensation, respectively, related to outstanding stock options. At June 30, 2024, the Company had \$366,400 of unrecognized expenses related to outstanding options. <p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes the stock option activity for the six months ended June 30, 2024.<p> <table cellpadding="0" cellspacing="0" id="xdx 883_eus-gaap-ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock zBgnOe85jHk2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; summary="xdx: Disclosure - Equity (Details - Option activity)"> <tr style="vertical-align: bottom;"> <td style="text-align: left;">Schedule of stock option activity</td> <td> </td> <td colspan="3" style="text-align: right;"> </td> <td> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td> <td colspan="3" style="text-align: right;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td style="text-align: left;"> </td> <td colspan="3" style="text-align: right;"> </td>

[illegible]

<td id="xdx_987_eus-gaap-
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember z0o0PMJXRaRl" style="text-align: right" title="Weighted-average exercise price per share granted">8.12</td><td style="text-align: left"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
<td style="text-align: left">Exercised</td><td><td style="text-align: left"></td><td id="xdx_981_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_in_di c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember zDdZKblheFmd" style="text-align: right" title="Warrants exercised">(253.034</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td id="xdx_981_ecustom-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice il c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember z8lzm1V2SCxd" style="text-align: right" title="Weighted-average exercise price per share exercised">13.18</td><td style="text-align: left"></td><td></td><tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Forfeited</td><td><td style="text-align: left"></td><td id="xdx_988_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0 c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember z8Et56wR4eL5" style="text-align: right" title="Warrants forfeited"></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td id="xdx_98C_ecustom-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice d0 c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember zzkSHB5TuMLk" style="text-align: right" title="Weighted-average exercise price per share forfeited"></td><td style="text-align: left"></td><td></td><tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
<td style="padding-bottom: 1pt; text-align: left">Expired</td><td style="padding-bottom: 1pt"></td><td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_985_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_in_di0 c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember zCcE9DND7FMl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">(70</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"></td><td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_988_ecustom-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice il d0 c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember z7iflrsLVua" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price per share expired">2.635</td><td style="padding-bottom: 1pt; text-align: left"></td><td></td><tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt; text-align: left">Outstanding, June 30, 2024</td><td style="padding-bottom: 2.5pt"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap-ClassOfWarrantOrRightOutstanding_ie c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember zyTaYpZF5Pn" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding at ending">1,551,422</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98E_eus-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 ie c20240101_20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember ziNp2dxGazs8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price per share at ending">15.03</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td></td><tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
<td style="padding-bottom: 2.5pt; text-align: left">Exercisable, June 30, 2024</td><td style="padding-bottom: 2.5pt"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_981_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_il c20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember zy4tU8BJKec" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">1,551,422</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_986_eus-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice il c20240630_us-gaap-AwardTypeAxis_custom-WarrantsMember zov3TOf4upJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price per share Exercisable">15.03</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td></td></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0">As of June 30, 2024, the outstanding and exercisable warrants have a weighted average remaining term of 4.22 years and had no aggregate intrinsic value.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0">Restricted Stock Units
On April 28, 2022, the Board of Directors granted officers and employees a total of 193 Restricted Stock Units that partially vest over 4 years. The Company valued the RSUs based on the stock price at grant which total 95,399. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0">On April 7, 2024, the Board of Directors approved grants of 5,330 RSUs to officers, employees, and board of directors. Of the 5,330 RSUs issued, 1,750 RSUs 3,580 RSUs vest on the first anniversary or at the time of the 2025 shareholder meeting, whichever occurs first and 3,580 RSUs vest in 8 equal quarterly installments over 2 years. The Company valued the RSUs based on the stock price at grant which total 69,027. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0">During the six months ended June 30, 2024, the Company recognized 19,566 of stock-based compensation, related to outstanding stock RSUs. At June 30, 2024, the Company had 103,123 of unrecognized expenses related to outstanding RSUs. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: Opt 0; background-color: white">The following table summarizes the RSUs activity for the six months ended June 30, 2024:</b

[illegible]

[illegible]

[illegible]

11